

第1章 肺癌筛查与预防

1. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209-249.
2. Sharma R. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. *Int J Clin Oncol.* 2022;27(4):665-675.
3. Husten CG, Deyton LR. Understanding the Tobacco Control Act: efforts by the US Food and Drug Administration to make tobacco-related morbidity and mortality part of the USA's past, not its future. *Lancet.* 2013;381(9877):1570-1580.
4. Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. *JAMA.* 2014;311(2):164.
5. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. *Transl Lung Cancer Res.* 2015;4(4):327-338.
6. Ordóñez-Mena JM, Schöttker B, Mons U, et al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. *BMC Med.* 2016;14(1):62.
7. Brennan P, Buffler PA, Reynolds P, et al. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. *Int J Cancer.* 2004;109(1):125-131.
8. Wong JYY, Bassig BA, Seow WJ, et al. Lung cancer risk in welders and foundry workers with a history of heavy smoking in the USA: The National Lung Screening Trial. *Occup Environ Med.* 2017;74(6):440-448.
9. National Lung Screening Trial Research Team; Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med.* 2011;365(5):395-409.
10. Hamra GB, Laden F, Cohen AJ, Raaschou-Nielsen O, Brauer M, Loomis D. Lung cancer and exposure to nitrogen dioxide and traffic: a systematic review and meta-analysis. *Environ Health Perspect.* 2015;123(11):1107-1112.
11. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. *Outdoor Air Pollution.* Lyon, France: International Agency for Research on Cancer, World Health Organization; 2016.
12. Gharibvand L, Shavlik D, Ghamsary M, et al. The association between ambient fine particulate air pollution and lung cancer incidence: results from the AHSMOG-2 Study. *Environ Health Perspect.* 2017;125(3):378-384.
13. Guo Y, Zeng H, Zheng R, et al. The association between lung cancer incidence and ambient air pollution in China: a spatiotemporal analysis. *Environ Res.* 2016;144:60-65.
14. Krewski D, Lubin JH, Zielinski JM, et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. *Epidemiology.* 2005;16(2):137-145.
15. Lubin JH, Boice JD. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. *J Natl Cancer Inst.* 1997;89(1):49-57.
16. Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *BMJ.* 2005;330(7485):223.
17. Maisonneuve P, Shivappa N, Hébert JR, et al. Dietary inflammatory index and risk of lung cancer and other respiratory conditions among heavy smokers in the COSMOS screening study. *Eur J Nutr.* 2016;55(3):1069-1079.
18. Vieira AR, Abar L, Vingeliene S, et al. Fruits, vegetables and lung cancer risk: a systematic review and meta-analysis. *Ann Oncol.* 2016;27(1):81-96.
19. *Cancer Trends Progress Report.* Bethesda, MD: National Cancer Institute, NIH, DHHS; 2019.
20. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (8th) edition of the TNM Classification for

- Lung Cancer. *J Thorac Oncol*. 2016;11(1):39-51.
21. Wilson JM, Jungner YG. [Principles and practice of mass screening for disease]. *Bol Oficina Sanit Panam*. 1968;65(4):281-393.
 22. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(1):7-30.
 23. Manser R, Lethaby A, Irving LB, et al. Screening for lung cancer. *Cochrane Database Syst Rev*. 2013;(6):CD001991.
 24. Brett GZ. The value of lung cancer detection by six-monthly chest radiographs. *Thorax*. 1968;23(4):414-420.
 25. Lilienfeld A. ACS-VA Cooperative Study for evaluation of radiologic and cytologic screening in the early detection of lung cancer: progress report. *Acta Unio Int Contra Cancrum*. 1963;19:1330-1334.
 26. Berlin NI, Buncher CR, Fontana RS, Frost JK, Melamed MR. The National Cancer Institute Cooperative Early Lung Cancer Detection Program. Results of the initial screen (prevalence). Early lung cancer detection: introduction. *Am Rev Respir Dis*. 1984;130(4):545-549.
 27. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. *J Occup Med*. 1986;28(8):746-750.
 28. Kubik AK, Parkin DM, Zatloukal P. Czech study on lung cancer screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. *Cancer*. 2000;89(suppl 11):2363-2368.
 29. Frost JK, Ball Jr WC, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. *Am Rev Respir Dis*. 1984;130(4):549-554.
 30. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. *Chest*. 1984;86(1):44-53.
 31. Hocking WG, Hu P, Oken MM, et al. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *J Natl Cancer Inst*. 2010;102(10):722-731.
 32. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. *JAMA*. 2011;306(17):1865-1873.
 33. Gohagan JK, Marcus PM, Fagerstrom RM, et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. *Lung Cancer*. 2005;47(1):9-15.
 34. Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial. *AJR Am J Roentgenol*. 2011;197(5):1165-1169.
 35. National Lung Screening Trial Research Team, Aberle DR, Berg CD, et al. The National Lung Screening Trial: overview and study design. *Radiology*. 2011;258(1):243-253.
 36. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. *Lancet*. 1999;354(9173):99-105.
 37. International Early Lung Cancer Action Program Investigators; Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. *N Engl J Med*. 2006;355(17):1763-1771.
 38. Henschke CI, Yankelevitz DF, Libby DM, et al. Early lung cancer action project: annual screening using single-slice helical CT. *Ann NY Acad Sci*. 2001;952:124-134.
 39. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. *Radiology*. 2005;235(1):259-265.
 40. National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial. *J Thorac Oncol*. 2019;14(10):1732-1742.
 41. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. *N Engl J Med*. 2020;382(6):503-513.
 42. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. *Eur Respir J*. 2013;42(6):1659-1667.
 43. Horeweg N, Scholten ET, de Jong PA, et al. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. *Lancet Oncol*. 2014;15(12):1342-1350.
 44. Heuvelmans MA, Walter JE, Vliegenthart R, et al. Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening. *Thorax*. 2018;73(8):779-781.

45. de Koning H, van der Aalst C, Ten Haaf K, Oudkerk M. Effects of volume CT lung cancer screening: mortality results of the NELSON Randomized-Controlled Population Based Trial. *J Thorac Oncol.* 2018;13(10):S185.
46. Becker N, Motsch E, Trotter A, et al. Lung cancer mortality reduction by LDCT screening—results from the randomized German LUSI trial. *Int J Cancer.* 2020;146(6):1503-1513.
47. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. *Cancer.* 2013;119(22):3976-3983.
48. Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE Trial, a randomized study of lung cancer screening with spiral computed tomography. *Am J Respir Crit Care Med.* 2015;191(10):1166-1175.
49. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. *Am J Respir Crit Care Med.* 2009;180(5):445-453.
50. Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized danish lung cancer screening trial with focus on high-risk profiling. *Am J Respir Crit Care Med.* 2016;193(5):542-551.
51. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. *Ann Oncol.* 2019;30(7):1162-1169.
52. Blanchon T, Brechot JM, Grenier PA, et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). *Lung Cancer.* 2007;58(1):50-58.
53. Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. *Health Technol Assess.* 2016;20(40):1-146.
54. Paci E, Puliti D, Lopes Pegna A, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. *Thorax.* 2017;72(9):825-831.
55. Lam S, Myers R, Ruparel M, et al. Lung cancer screenee selection by USPSTF versus PLCOm2012 criteria-interim ILST findings. *J Thorac Oncol.* 2019;14(10S):S4-S5.
56. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. *N Engl J Med.* 2013;368(8):728-736.
57. Patz EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. *JAMA Intern Med.* 2014;174(2):269.
58. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin.* 2017;67(2):100-121.
59. Tanner NT, Kanodra NM, Gebregziabher M, et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. *Am J Respir Crit Care Med.* 2016;193(5):534-541.
60. Bach PB, Brawley OW, Silvestri GA. Low-dose CT for lung cancer screening. *Lancet Oncol.* 2018;19(3):e133-e134.
61. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. *Lancet Oncol.* 2017;18(12):e754-e766.
62. Wender R, Fontham ETH, Barrera E, et al. American Cancer Society lung cancer screening guidelines. *CA Cancer J Clin.* 2013;63(2):106-117.
63. Joseph AM, Rothman AJ, Almirall D, et al. Lung cancer screening and smoking cessation clinical trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) collaboration. *Am J Respir Crit Care Med.* 2018;197(2):172-182.
64. Pistelli F, Aquilini F, Falaschi F, et al. Smoking cessation in the ITALUNG lung cancer screening: what does “teachable moment” mean? *Nicotine Tob Res.* 2020;22(9):1484-1491.
65. Brain K, Carter B, Lifford KJ, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. *Thorax.* 2017;72(10):912-918.
66. Tammemägi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. *J Natl Cancer Inst.* 2014;106(6):dju084.

67. Chiles C, Duan F, Gladish GW, et al. Association of coronary artery calcification and mortality in the National Lung Screening Trial: a comparison of three scoring methods. *Radiology*. 2015;276(1):82-90.
68. Morgan L, Choi H, Reid M, Khawaja A, Mazzone PJ. Frequency of incidental findings and subsequent evaluation in low-dose computed tomographic scans for lung cancer screening. *Ann Am Thorac Soc*. 2017;14(9):1450-1456.
69. Harris RP, Sheridan SL, Lewis CL, et al. The harms of screening: a proposed taxonomy and application to lung cancer screening. *JAMA Intern Med*. 2014;174(2):281-285.
70. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer. *JAMA*. 2012;307(22):2418.
71. Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. What do you mean, a spot? *Chest*. 2013;143(3):672-677.
72. Van Den Bergh KAM, Essink-Bot ML, Borsboom GJJM, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). 2010;102(1):27-34.
73. Caverly TJ, Fagerlin A, Wiener RS, et al. Comparison of observed harms and expected mortality benefit for persons in the Veterans Health Affairs Lung Cancer Screening Demonstration Project. *JAMA Intern Med*. 2018;178(3):426-428.
74. Henschke CI, Yip R, Yankelevitz DF, Smith JP; International Early Lung Cancer Action Program Investigators. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. *Ann Intern Med*. 2013;158(4):246-252.
75. *Lung-RADS Version 1.1*. 2019. Available at: <https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf?la=en>. Accessed December 18, 2019.
76. Pinsky PF. Assessing the benefits and harms of low-dose computed tomography screening for lung cancer. *Lung Cancer Manag*. 2014;3(6):491-498.
77. Heleno B, Siersma V, Brodersen J. Estimation of overdiagnosis of lung cancer in low-dose computed tomography screening. *JAMA Intern Med*. 2018;178(10):1420.
78. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side effects of breast cancer screening. *Health Psychol*. 1991;10(4):259.
79. Lampic C, Thurfjell E, Bergh J, Sjöden P-O. Short- and long-term anxiety and depression in women recalled after breast cancer screening. *Eur J Cancer*. 2001;37(4):463-469.
80. Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. *Med Decis Making*. 2008;28(6):917-925.
81. Gareen IF, Duan F, Greco EM, et al. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. *Cancer*. 2014;120(21):3401-3409.
82. Kong CY, Sigel K, Criss SD, et al. Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/ μ l. *AIDS*. 2018;32(10):1333-1342.
83. Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. *Ann Intern Med*. 2013;159(6):411-420.
84. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;160(5):330-338.
85. US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;325(10):962-970.
86. Final National Coverage Determination on Screening for Lung Cancer with Low Dose Computed Tomography (LDCT). CMS. Available at: <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=2742015>.
87. Wood DE, Kazerooni EA, Baum SL, et al. Lung cancer screening, version 3.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2018;16(4):412-441.
88. Tammemagi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. *PLoS Med*. 2014;11(12):e1001764.

89. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. *Ann Intern Med.* 2015;162(7):485-491.
90. Mazzone PJ, Silvestri GA, Patel S, et al. Screening for lung cancer: CHEST Guideline and Expert Panel Report. *Chest.* 2018;153(4):954-985.
91. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thorac Cardiovasc Surg.* 2012;144(1):33-38.
92. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. *N Engl J Med.* 2014;371(19):1793-1802.
93. Wade S, Weber M, Caruana M, et al. Estimating the cost-effectiveness of lung cancer screening with low-dose computed tomography for high-risk smokers in Australia. *J Thorac Oncol.* 2018;13(8):1094-1105.
94. Tailor TD, Tong BC, Gao J, Henderson LM, Choudhury KR, Rubin GD. Utilization of lung cancer screening in the Medicare fee-for-service population. *Chest.* 2020;158(5):2200-2210.
95. Weber M, Yap S, Goldsbury D, et al. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCOm2012 risk prediction tool. *Int J Cancer.* 2017;141(2):242-253.
96. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States—2010 to 2015. *JAMA Oncol.* 2017;3(9):1278-1281.
97. Thomson CC, McKee AB. American Thoracic Society/American Lung association lung cancer screening implementation guide. *Am J Respir Crit Care Med.* 2018;198(9):1120-1121.
98. Fintelmann FJ, Bernheim A, Digumarthy SR, et al. The 10 pillars of lung cancer screening: rationale and logistics of a lung cancer screening program. *Radiographics.* 2015;35(7):1893-1908.
99. Raz DJ, Wu G, Nelson RA, et al. Perceptions and utilization of lung cancer screening among smokers enrolled in a tobacco cessation program. *Clin Lung Cancer.* 2019;20(1):e115-e122.
100. Raz DJ, Wu GX, Consunji M, et al. Perceptions and utilization of lung cancer screening among primary care physicians. *J Thorac Oncol.* 2016;11(11):1856-1862.
101. AHRQ. Is lung cancer screening right for me? AHRQ Publication No. 16-EHC007-12-A. 2016. Available at: <https://effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/lung-cancer-screening-decision-aid.pdf>.
102. *Decision Aid for Lung Cancer Screening with Computerized Tomography (CT)*. New York, NY: American Thoracic Society; 2015.
103. Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. *PLoS One.* 2013;8(8):e71379.
104. *Lung Cancer Screening Coverage in State Medicaid Programs*. 2019. Available at: <https://www.lung.org/getmedia/501f87d1-b3b1-4c1e-bc63-185d2ec10b7b/Coverage-Table-3-7-2023.pdf>. Accessed December 18, 2019.
105. Carter-Harris L, Gould MK. Multilevel barriers to the successful implementation of lung cancer screening: why does it have to be so hard? *Ann Am Thorac Soc.* 2017;14(8):1261-1265.
106. Hall IJ, Tangka FKL, Sabatino SA, Thompson TD, Graubard BI, Breen N. Patterns and trends in cancer screening in the United States. *Prev Chronic Dis.* 2018;15:E97.
107. Liu B, Dharmarajan K, Henschke CI, Taioli E. State-level variations in the utilization of lung cancer screening among Medicare fee-for-service beneficiaries: an analysis of the 2015-2017 Physician and Other Supplier data. *Chest.* 2020;157(4):1012-1020.
108. Li J, Chung S, Wei EK, Luft HS. New recommendation and coverage of low-dose computed tomography for lung cancer screening: uptake has increased but is still low. *BMC Health Serv Res.* 2018;18(1):525.
109. Tailor TD, Choudhury KR, Tong BC, Christensen JD, Sosa JA, Rubin GD. Geographic access to CT for lung cancer screening: a census tract-level analysis of cigarette smoking in the United States and driving distance to a CT facility. *J Am Coll Radiol.* 2019;16(1):15-23.
110. Richards TB, Doria-Rose VP, Soman A, et al. Lung cancer screening inconsistent with US Preventive Services Task Force Recommendations. *Am J Prev Med.* 2019;56(1):66-73.

111. *Smoking Rates for Uninsured and Adults on Medicaid More Than Twice Those for Adults with Private Health Insurance*. Published 2015. Available at: <https://www.cdc.gov/media/releases/2015/p1112-smoking-rates.html>. Accessed December 20, 2019.
112. Huo J, Shen C, Volk RJ, Shih YT. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake. *JAMA Intern Med*. 2017;177(3):439-441.
113. Katki HA, Kovalchik SA, Petito LC, et al. Implications of nine risk prediction models for selecting ever-smokers for computed tomography lung cancer screening. *Ann Intern Med*. 2018;169(1):10-19.
114. Kumar V, Cohen JT, van Klaveren D, et al. Risk-targeted lung cancer screening: a cost-effectiveness analysis. *Ann Intern Med*. 2018;168(3):161-169.
115. Pastorino U, Boeri M, Sestini S, et al. PL02. 04 blood microRNA and LDCT reduce unnecessary LDCT repeats in lung cancer screening: results of prospective BioMILD Trial. *J Thorac Oncol*. 2019;14(10):S5-S6.
116. Guirao A, Molins L, Ramón I, et al. Trained dogs can identify malignant solitary pulmonary nodules in exhaled gas. *Lung Cancer*. 2019;135:230-233.
117. Lee G, Lee HY, Park H, et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: state of the art. *Eur J Radiol*. 2017;86:297-307.
118. Lafata K, Cai J, Wang C, Hong J, Kelsey CR, Yin F-F. Spatial-temporal variability of radiomic features and its effect on the classification of lung cancer histology. *Phys Med Biol*. 2018;63(22):225003.
119. Hawkins S, Wang H, Liu Y, et al. Predicting malignant nodules from screening CT scans. *J Thoracic Oncol*. 2016;11(12):2120-2128.

第2章 肺癌:诊断技术

1. Adler I. Primary malignant growths of the lungs and bronchi: a pathological and clinical study. London, England: Longmans, Green; 1912.
2. Wender R, Fontham ET, Barrera Jr E, et al. American Cancer Society lung cancer screening guidelines. *CA Cancer J Clin.* 2013;63:106-117.
3. Spiro SG, Silvestri GA. One hundred years of lung cancer. *Am J Respir Crit Care Med.* 2005;172:523-529.
4. Hammond EC, Horn D. The relationship between human smoking habits and death rates: a follow-up study of 187,766 men. *J Am Med Assoc.* 1954;155:1316-1328.
5. Smoking USSGsACo. Smoking and health: report of the advisory committee to the Surgeon General of the Public Health Service. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service; 1964.
6. Doll R, Hill AB. Smoking and carcinoma of the lung. *Br Med J.* 1950;2:739.
7. Control CDC, Prevention. *Current Cigarette Smoking Among Adults in the United States. Smoking & Tobacco Use.* Available at: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/. Accessed October 10, 2018.
8. Investigators IELCAP. Survival of patients with stage I lung cancer detected on CT screening. *N Engl J Med.* 2006;355:1763-1771.
9. Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. *Lancet Oncol.* 2016;17:907-916.
10. Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). London, England: SAGE Publications Sage UK; 2011.
11. De Koning H, Van Der Aalst C, Ten Haaf K, Oudkerk M. Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. *J Thorac Oncol.* 2018;13:S185.
12. Gould MK, Tang T, Liu I-LA, et al. Recent trends in the identification of incidental pulmonary nodules. *Am J Respir Crit Care Med.* 2015;192:1208-1214.
13. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. *Chest.* 2017;151:193-203.
14. Thomas CR Jr. Lung cancer: a multidisciplinary approach to diagnosis and management. Demos Medical Publishing; New York City, New York, USA 2010.
15. Bradley S, Abraham S, Grice A, et al. Sensitivity of chest x-ray for lung cancer: systematic review. *Br J Gen Pract.* 2018;68:bjgp18X696905.
16. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2013;143:e78S-e92S.
17. Muhm JR, Miller W, Fontana R, Sanderson D, Uhlenhopp M. Lung cancer detected during a screening program using four-month chest radiographs. *Radiology.* 1983;148:609-615.
18. Frost JK, Ball Jr WC, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. *Am Rev Respir Dis.* 1984;130:549-554.
19. Kocher F, Lunger F, Seeber A, et al. Incidental diagnosis of asymptomatic non-small-cell lung cancer: a registry-based analysis. *Clin Lung Cancer.* 2016;17:62-67.e1.
20. Tamura T, Kurishima K, Nakazawa K, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. *Mol Clin Oncol.* 2015;3:217-221.

21. Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA, et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. *J Clin Oncol*. 2005;23: 8348-8356.
22. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143:e211S-e250S.
23. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. *Chest*. 2003;123:137S-146S.
24. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. *Radiology*. 1992;182:319-323.
25. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. *N Engl J Med*. 2003;348:2500-2507.
26. Antoch G, Statta J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. *Radiology*. 2003;229:526-533.
27. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. *Ann Intern Med*. 2003;139:879-892.
28. Herder G, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. *J Clin Oncol*. 2006;24:1800-1806.
29. Nair V, Barnett P, Ananth L, Gould M; Veterans Affairs Solitary Nodule Accuracy Project Cooperative Studies Group. Positron emission tomography (PET) 18F-fluorodeoxyglucose (FDG) uptake and prognosis in patients with resected, clinical stage IA non-small cell lung cancer. *Chest*. 2009;137:1150-1156.
30. Wang J, Welch K, Wang L. Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis. *Clin Lung Cancer*. 2012;13:81-89.
31. Kanzaki R, Higashiyama M, Fujiwara A, et al. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: risk factors, pattern, and histopathological study. *Lung Cancer*. 2011;71:333-337.
32. Li S, Zheng Q, Ma Y, et al. Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of 18F-FDG PET/CT. *PLoS One*. 2013;8:e78552.
33. Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer? ACCP evidence-based clinical practice guidelines. *Chest*. 2007;132:108S-130S.
34. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol*. 2016;11:39-51.
35. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143:e93S-e120S.
36. Cummings SR, Lillington GA, Richard RJ. Estimating the probability of malignancy in solitary pulmonary nodules: a Bayesian approach. *Am Rev Respir Dis*. 1986;134:449-452.
37. Swensen SJ, Silverstein MD, Edell ES, et al. Solitary pulmonary nodules: clinical prediction model versus physicians. *Mayo Clin Proc*. 1999;74(4):319-329. Available at: [https://www.mayoclinicproceedings.org/article/S0025-6196\(11\)64397-8/fulltext](https://www.mayoclinicproceedings.org/article/S0025-6196(11)64397-8/fulltext).
38. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. *N Engl J Med*. 2013;369:910-919.
39. Tanner NT, Porter A, Gould MK, Li X-J, Vachani A, Silvestri GA. Physician assessment of pretest probability of malignancy and adherence with guidelines for pulmonary nodule evaluation. *Chest*. 2017;152:263-270.
40. Rivera MP, Detterbeck F, Mehta AC. Diagnosis of lung cancer: the guidelines. *Chest*. 2003;123: 129S-136S.

41. Ikeda S, Yanai N, Ishikawa S. Flexible bronchofiberscope. *Keio J Med.* 1968;17:1-16.
42. Miller RJ, Casal RF, Lazarus DR, Ost DE, Eapen GA. Flexible bronchoscopy. *Clin Chest Med.* 2018;39:1-16.
43. McLean A, Semple P, Franklin D, Petrie G, Millar E, Douglas J. The Scottish multi-centre prospective study of bronchoscopy for bronchial carcinoma and suggested audit standards. *Respir Med.* 1998;92:1110-1115.
44. Gellert AR, Rudd RM, Sinha G, Geddes DM. Fiberoptic bronchoscopy: effect of multiple bronchial biopsies on diagnostic yield in bronchial carcinoma. *Thorax.* 1982;37:684-687.
45. Wassermann K, Gassanov N, Atay Z, Topalidis T, Dienes HP, Mathen F. The impact of cytology on the bronchoscopic diagnosis of lung cancer. *J Bronchol Intervent Pulmonol.* 2004;11:154-159.
46. Wahidi MM, Rocha AT, Hollingsworth JW, Govert JA, Feller-Kopman D, Ernst A. Contraindications and safety of transbronchial lung biopsy via flexible bronchoscopy. *Respiration.* 2005;72:285-295.
47. Bhatnagar R, Kahan BC, Morley AJ, et al. The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. *Trials.* 2015;16:48.
48. Herth F, Ernst A, Becker H. Endobronchial ultrasound-guided transbronchial lung biopsy in solitary pulmonary nodules and peripheral lesions. *Eur Respir J.* 2002;20:972-974.
49. Yamamoto S, Ueno K, Imamura F, et al. Usefulness of ultrathin bronchoscopy in diagnosis of lung cancer. *Lung Cancer.* 2004;46:43-48.
50. Chen A, Chenna P, Loiselle A, Massoni J, Mayse M, Misselhorn D. Radial probe endobronchial ultrasound for peripheral pulmonary lesions. A 5-year institutional experience. *Ann Am Thorac Soc.* 2014;11:578-582.
51. Morton C, Puchalski J. The utility of bronchoscopy in immunocompromised: a review. *J Thorac Dis.* 2019;11(12):5603-5612. Available at: <https://jtd.amegroups.com/article/view/32524/html>.
52. Strumpf IJ, Feld MK, Cornelius MJ, Keogh BA, Crystal RG. Safety of fiberoptic bronchoalveolar lavage in evaluation of interstitial lung disease. *Chest.* 1981;80:268-271.
53. Friets EM, Strohbehn JW, Hatch JF, Roberts DW. A frameless stereotaxic operating microscope for neurosurgery. *IEEE Trans Biomed Eng.* 1989;36:608-617.
54. Grevers G, Menauer F, Leunig A, Caversaccio M, Kastenbauer E. Navigation surgery in diseases of the paranasal sinuses. *Laryngorhinootologie.* 1999;78:41-46.
55. Folch EE, Bowling MR, Gildea TR, et al. Design of a prospective, multicenter, global, cohort study of electromagnetic navigation bronchoscopy. *BMC Pulm Med.* 2016;16:60.
56. Pickering EM, Kalchiem-Dekel O, Sachdeva A. Electromagnetic navigation bronchoscopy: a comprehensive review. *AME Med J.* 2018;3.
57. Folch EE, Pritchett MA, Nead MA, et al. Electromagnetic navigation bronchoscopy for peripheral pulmonary lesions: one-year results of the prospective, multicenter NAVIGATE study. *J Thorac Oncol.* 2019;14:445-458.
58. Semaan R, Yarmus L. Rigid bronchoscopy and silicone stents in the management of central airway obstruction. *J Thorac Dis.* 2015;7:S352.
59. Aboudara M, Roller L, Rickman O, et al. Improved diagnostic yield for lung nodules with digital tomosynthesis-corrected navigational bronchoscopy: initial experience with a novel adjunct. *Respirology.* 2020;25(2):206-213. Available at: <https://onlinelibrary.wiley.com/doi/10.1111/resp.13609>.
60. Casal RF. Cone beam CT-guided bronchoscopy: here to stay? *J Bronchology Interv Pulmonol.* 2018;25:255-256.
61. Silvestri GA, Herth FJ, Keast T, et al. Feasibility and safety of bronchoscopic transparenchymal nodule access in canines: a new real-time image-guided approach to lung lesions. *Chest.* 2014;145:833-838.
62. Serman DH, Keast T, Rai L, et al. High yield of bronchoscopic transparenchymal nodule access real-time image-guided sampling in a novel model of small pulmonary nodules in canines. *Chest.* 2015;147:700-707.
63. Herth FJ, Eberhardt R, Serman D, Silvestri GA, Hoffmann H, Shah PL. Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules. *Thorax.* 2015;70:326-332.

64. Harzheim D, Sterman D, Shah PL, Eberhardt R, Herth FJ. Bronchoscopic transparenchymal nodule access: feasibility and safety in an endoscopic unit. *Respiration*. 2016;91:302-306.
65. Pritchett M. Feasibility of the LungVision augmented endobronchial fluoroscopic navigation and localization system: comparison with cone beam CT for nodule localization. *Chest*. 2017;152:A863.
66. Stoy S, Hogarth D, Al-Zubaidi A, Whitten P. Bronchoscopic peripheral lung nodule navigation by a novel live endobronchial fluoroscopic navigation and guidance system technology: insights from the Multicenter Lungvision I Trial. *Chest*. 2017;152:A757.
67. Abi-Jaoudeh N, Kruecker J, Kadoury S, et al. Multimodality image fusion-guided procedures: technique, accuracy, and applications. *Cardiovasc Intervent Radiol*. 2012;35:986-998.
68. Abi-Jaoudeh N, Fisher T, Jacobus J, et al. Prospective randomized trial for image-guided biopsy using cone-beam CT navigation compared with conventional CT. *J Vasc Interv Radiol*. 2016;27:1342-1349.
69. Rotolo N, Floridi C, Imperatori A, et al. Comparison of cone-beam CT-guided and CT fluoroscopy-guided transthoracic needle biopsy of lung nodules. *Eur Radiol*. 2016;26:381-389.
70. Lee SM, Park CM, Lee KH, Bahn YE, Kim JI, Goo JM. C-arm cone-beam CT-guided percutaneous transthoracic needle biopsy of lung nodules: clinical experience in 1108 patients. *Radiology*. 2013;271:291-300.
71. Hohenforst-Schmidt W, Zarogoulidis P, Vogl T, et al. Cone beam computed tomography (CBCT) in interventional chest medicine-high feasibility for endobronchial realtime navigation. *J Cancer*. 2014;5:231.
72. Casal RF, Sarkiss M, Jones AK, et al. Cone beam computed tomography-guided thin/ultrathin bronchoscopy for diagnosis of peripheral lung nodules: a prospective pilot study. *J Thorac Dis*. 2018;10:6950.
73. Pritchett MA, Schampaert S, de Groot JA, Schirmer CC, van der Bom I. Cone-beam CT with augmented fluoroscopy combined with electromagnetic navigation bronchoscopy for biopsy of pulmonary nodules. *J Bronchology Interv Pulmonol*. 2018;25:274.
74. Ali EA, Takizawa H, Kawakita N, et al. Transbronchial biopsy using an ultrathin bronchoscope guided by cone-beam computed tomography and virtual bronchoscopic navigation in the diagnosis of pulmonary nodules. *Respiration*. 2019;1-8.
75. Murgu SD. Robotic assisted-bronchoscopy: technical tips and lessons learned from the initial experience with sampling peripheral lung lesions. *BMC Pulm Med*. 2019;19:89.
76. Chen AC, Gillespie CT. Robotic endoscopic airway challenge: REACH assessment. *Ann Thorac Surg*. 2018;106:293-297.
77. Chen A, Gildea T, Gillespie C, et al. Robotic-assisted bronchoscopic biopsy of peripheral pulmonary lesions in a cadaveric model with simulated tumor targets. *Chest*. 2018;154.
78. Rojas-Solano JR, Ugalde-Gamboa L, Machuzak M. Robotic bronchoscopy for diagnosis of suspected lung cancer: a feasibility study. *J Bronchology Interv Pulmonol*. 2018;25:168.
79. Fielding DI, Bashirzadeh F, Son JH, et al. First human use of a new robotic-assisted fiber optic sensing navigation system for small peripheral pulmonary nodules. *Respiration*. 2019;98:142-150.
80. Laurent F, Latrabe V, Vergier B, Montaudon M, Vernejoux J-M, Dubrez J. CT-guided transthoracic needle biopsy of pulmonary nodules smaller than 20 mm: results with an automated 20-gauge coaxial cutting needle. *Clin Radiol*. 2000;55:281-287.
81. Beslic S, Zukic F, Misilic S. Percutaneous transthoracic CT guided biopsies of lung lesions; fine-needle aspiration biopsy versus core biopsy. *Radiol Oncol*. 2012;46(1):19-22.
82. Oikonomou A, Matzinger FR, Seely JM, Dennie CJ, Macleod PJ. Ultrathin needle (25 G) aspiration lung biopsy: diagnostic accuracy and complication rates. *Eur Radiol*. 2004;14:375-382.
83. Heerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R, Oudkerk M. Complication rates of CT-guided transthoracic lung biopsy: meta-analysis. *Eur Radiol*. 2017;27:138-148.
84. DiBardino DM, Yarmus LB, Semaan RW. Transthoracic needle biopsy of the lung. *J Thorac Dis*. 2015;7:S304.
85. Ayar D, Golla B, Lee JY, Nath H. Needle-track metastasis after transthoracic needle biopsy. *J Thorac Imaging*. 1998;13:2-6.
86. Kinsey CM, Arenberg DA. Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging. *Am J Respir Crit Care Med*. 2014;189:640-649.

87. Eapen G, Shah A, Lei X, et al. Complications, consequences, and practice patterns of EBUS-TBNA: results of the AQuIRE registry. *Chest*. 2013;143:1044-1053.
88. Detterbeck F, Puchalski J, Rubinowitz A, Cheng D. Classification of the thoroughness of mediastinal staging of lung cancer. *Chest*. 2010;137:436-442.
89. Sehgal IS, Dhooira S, Aggarwal AN, Agarwal R. Impact of rapid on-site cytological evaluation (ROSE) on the diagnostic yield of transbronchial needle aspiration during mediastinal lymph node sampling: systematic review and meta-analysis. *Chest*. 2018;153:929-938.
90. Sakakibara R, Inamura K, Tambo Y, et al. EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer. *Clin Lung Cancer*. 2017;18:527-534.
91. Folch E, Yamaguchi N, VanderLaan PA, et al. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. *J Thoracic Oncol*. 2013;8:1438-1444.
92. De Leyn P, Doooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. *Eur J Cardiothorac Surg*. 2014;45:787-798.
93. Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. *J Thorac Cardiovasc Surg*. 2011;142:1393-1400.e1.
94. Ernst A, Anantham D, Eberhardt R, Krasnik M, Herth FJ. Diagnosis of mediastinal adenopathy—real-time endobronchial ultrasound guided needle aspiration versus mediastinoscopy. *J Thorac Oncol*. 2008;3:577-582.
95. Taverner J, Cheang M-Y, Antippa P, See K, Irving LB, Steinfort DP. Negative EBUS-TBNA predicts very low prevalence of mediastinal disease in staging of non-small cell lung cancer. *J Bronchology Interv Pulmonol*. 2016;23:177-180.
96. Ong P, Grosu H, Eapen GA, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for systematic nodal staging of lung cancer in patients with N0 disease by computed tomography and integrated positron emission tomography-computed tomography. *Ann Am Thorac Soc*. 2015;12:415-419.
97. Vial MR, O'Connell OJ, Grosu HB, et al. Diagnostic performance of endobronchial ultrasound-guided mediastinal lymph node sampling in early stage non-small cell lung cancer: a prospective study. *Respirology*. 2018;23:76-81.
98. Kang HJ, Hwangbo B, Lee G-K, et al. EBUS-centred versus EUS-centred mediastinal staging in lung cancer: a randomised controlled trial. *Thorax*. 2014;69:261-268.
99. Crombag L, Stigt J, Doooms C, et al. Added value of EUS-B to EBUS for lung cancer staging. *Eur Respirat Soc*. 2015;46:PA772. Available at: https://erj.ersjournals.com/content/46/suppl_59/PA772.
100. Lee KJ, Suh GY, Chung MP, et al. Combined endobronchial and transesophageal approach of an ultrasound bronchoscope for mediastinal staging of lung cancer. *PLoS One*. 2014;9:e91893.
101. Rodriguez-Panadero F, Naranjo FB, Mejias JL. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. *Eur Respir J*. 1989;2:366-369.
102. Antony V, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. *Eur Respir J*. 2001;18:402-419.
103. Hsu C. Cytologic detection of malignancy in pleural effusion: a review of 5,255 samples from 3,811 patients. *Diagn Cytopathol*. 1987;3:8-12.
104. Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines. *Chest*. 2007;132:131S-148S.
105. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. *Mayo Clin Proc*. 1985;60(3):158-164. doi:10.1016/s0025-6196(12)60212-2
106. Rahman NM, Gleeson FV. Image-guided pleural biopsy. *Curr Opin Pulm Med*. 2008;14:331-336.
107. Metintaş M, Ozdemir N, Işıksoy S, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. *J Comput Assist Tomogr*. 1995;19:370-374.

108. Maskell N, Gleeson F, Davies R. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. *Lancet*. 2003;361:1326-1330.
109. Wan Y-Y, Zhai C-C, Lin X-S, et al. Safety and complications of medical thoracoscopy in the management of pleural diseases. *BMC Pulm Med*. 2019;19:125.
110. Silvestri GA, Vachani A, Whitney D, et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. *N Engl J Med*. 2015;373:243-251.
111. Silvestri GA, Tanner NT, Kearney P, et al. Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial. *Chest*. 2018;154:491-500.

第3章 组织学和分子检测

1. Travis WD, Burke BE, Marx AP, Nicholson AG. *WHO Classification of Tumors of Lung, Pleura, Thymus, and Heart*. 4th ed. Lyon, France: IARC; 2015.
2. Travis WD. The 2015 WHO classification of lung tumors. *Pathologe*. 2014;35(suppl 2):188.
3. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. *J Thorac Oncol*. 2015;10:1243-1260.
4. Lamb D. Histological classification of lung cancer. *Thorax*. 1984;39:161-165.
5. Shimosato Y, Suzuki A, Hashimoto T, et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. *Am J Surg Pathol*. 1980;4:365-373.
6. Russell PA, Barnett SA, Walkiewicz M, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. *J Thorac Oncol*. 2013;8:461-468.
7. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. *J Thorac Oncol*. 2011;6:1496-1504.
8. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. *Lung Cancer*. 2013;81:371-376.
9. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol*. 2011;6:244-285.
10. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Modern Pathol*. 2011;24:653-664.
11. Behera M, Owonikoko TK, Gal AA, et al. Lung adenocarcinoma staging using the 2011 IASLC/ATS/ERS Classification: a pooled analysis of adenocarcinoma in situ and minimally invasive adenocarcinoma. *Clin Lung Cancer*. 2016;17:e57-e64.
12. Tsao MS, Marguet S, Le Teuff G, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. *J Clin Oncol*. 2015;33:3439-3446.
13. Warth A, Muley T, Kossakowski C, et al. Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma. *J Thorac Oncol*. 2015;10:638-644.
14. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. *Lung Cancer*. 2014;84:121-126.
15. Lee MC, Buitrago DH, Kadota K, Jones DR, Adusumilli PS. Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas. *Lung Cancer Manag*. 2014;3:245-253.
16. Kadota K, Nitadori JI, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. *J Thorac Oncol*. 2015;10:806-814.
17. Pyo JS, Kim JH. Clinicopathological significance of micropapillary pattern in lung adenocarcinoma. *Pathol Oncol Res*. 2018;24:547-555.
18. Hwang DH, Szeto DP, Perry AS, Bruce JL, Sholl LM. Pulmonary large cell carcinoma lacking squamous

- differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. *Arch Pathol Lab Med.* 2014;138:626-635.
19. Morales-Oyarvide V, Mino-Kenudson M. High-grade lung adenocarcinomas with micropapillary and/or solid patterns: a review. *Curr Opin Pulm Med.* 2014;20:317-323.
 20. Zhang Y, Wang R, Li Y, et al. Negative thyroid transcription factor 1 expression defines an unfavorable subgroup of lung adenocarcinomas. *J Thorac Oncol.* 2015;10:1444-1450.
 21. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. *J Mol Diagn.* 2007;9:320-326.
 22. Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. *Mod Pathol.* 2013;26:1307-1319.
 23. Kadota K, Yeh YC, D'Angelo SP, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. *Am J Surg Pathol.* 2014;38:1118-1127.
 24. Hwang DH, Sholl LM, Rojas-Rudilla V, et al. KRAS and NKX2-1 mutations in invasive mucinous adenocarcinoma of the lung. *J Thorac Oncol.* 2016;11:496-503.
 25. Duruisseau M, McLeer-Florin A, Antoine M, et al. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma. *Cancer Med.* 2016;5:3579-3585.
 26. Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. *Cancer Discov.* 2014;4:415-422.
 27. Moro-Sibilot D, Lantuejoul S, Diab S, et al. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. *Eur Respir J.* 2008;31:854-859.
 28. An N, Leng X, Wang X, Sun Y, Chen Z. Survival comparison of three histological subtypes of lung squamous cell carcinoma: a population-based propensity score matching analysis. *Lung Cancer.* 2020;142:13-19.
 29. Yuan G, Zhan C, Huang Y, et al. Clinical characteristics and prognosis of basaloid squamous cell carcinoma of the lung: a population-based analysis. *PeerJ.* 2019;7:e6724.
 30. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. *Int J Cancer.* 2005;117:294-299.
 31. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. *Lung Cancer.* 2001;31:139-148.
 32. Yesner R. Re: 'Effect of cigarette smoking on major histological types of lung cancer' SA Khuder, HH Dayal, AB Mutgi, et al. *Lung Cancer.* 1998;22:15-21. *Lung Cancer* 1999;24:45.
 33. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. *Am J Surg Pathol.* 2002;26:1184-1197.
 34. Rooper LM, Sharma R, Li QK, Illei PB, Westra WH. INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and cd56 for diagnosing neuroendocrine tumors of the thoracic cavity. *Am J Surg Pathol.* 2017;41:1561-1569.
 35. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. *Nature.* 2015;524:47-53.
 36. Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. *Nat Rev Cancer.* 2019;19:289-297.
 37. Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. *Clin Cancer Res.* 2016;22:3618-3629.
 38. Simbolo M, Barbi S, Fassan M, et al. Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations. *J Thorac Oncol.* 2019;14:1651-1661.
 39. Alcala N, Leblay N, Gabriel AAG, et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. *Nat Commun.* 2019;10:3407.

40. Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. *J Clin Oncol.* 2016;34:794-802.
41. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. *J Thorac Oncol.* 2015;10:990-1003.
42. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol.* 2016;11:39-51.
43. Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM Classification for Lung Cancer. *J Thorac Oncol.* 2015;10:1675-1684.
44. Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM Classification of Lung Cancer. *J Thorac Oncol.* 2015;10:1515-1522.
45. Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM Classification for Lung Cancer. *J Thorac Oncol.* 2016;11:300-311.
46. Travis WD, Asamura H, Bankier AA, et al. The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM Classification of Lung Cancer. *J Thorac Oncol.* 2016;11:1204-1223.
47. Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM Classification for Lung Cancer. *J Thorac Oncol.* 2016;11:651-665.
48. Detterbeck FC, Bolejack V, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM Classification for lung cancer. *J Thorac Oncol.* 2016;11:681-692.
49. Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. *J Thorac Oncol.* 2016;11:666-680.
50. Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC Lung Cancer Staging Project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. *J Thorac Oncol.* 2016;11:639-650.
51. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. *J Clin Oncol.* 2013;31:1039-1049.
52. Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. *N Engl J Med.* 2016;374:1864-1873.
53. Masciaux C, Tsao MS, Hirsch FR. Genomic testing in lung cancer: past, present, and future. *J Natl Compr Canc Netw.* 2018;16:323-334.
54. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science.* 2004;304:1497-1500.
55. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2004;350:2129-2139.
56. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A.* 2004;101:13306-13311.
57. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. *Cancer Discov.* 2017;7:137-155.

58. Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. *J Thorac Oncol.* 2017;12:1611-1625.
59. Leonetti A, Facchinetti F, Rossi G, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. *Cancer Treat Rev.* 2018;66:82-94.
60. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol.* 2018;15:731-747.
61. Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne? *Cancer Treat Rev.* 2020;84:101974.
62. Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. *Cancer Discov.* 2015;5:842-849.
63. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. *Nat Rev Clin Oncol.* 2018;15:151-167.
64. Subramanian J, Katta A, Masood A, Vudem DR, Kancha RK. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers. *Oncologist.* 2019;24:e1303-e1314.
65. Drilon A, Somwar R, Mangatt BP, et al. Response to ERBB3-directed targeted therapy in nrg1-rearranged cancers. *Cancer Discov.* 2018;8:686-695.
66. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. *Eur J Cancer.* 2001;37(suppl)4, S3-8.
67. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. *Curr Opin Cell Biol.* 2007;19:124-134.
68. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer.* 2007;7:169-181.
69. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene.* 2009;28(suppl 1):S24-S31.
70. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. *Annu Rev Pathol.* 2011;6:49-69.
71. Yoon HY, Ryu JS, Sim YS, et al. Clinical significance of EGFR mutation types in lung adenocarcinoma: a multi-centre Korean study. *PLoS One.* 2020;15:e0228925.
72. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncol.* 2015;16:830-838.
73. Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. *J Thorac Oncol.* 2020;15:803-815.
74. Skoulidis F, Papadimitrakopoulou VA. Targeting the gatekeeper: osimertinib in EGFR T790M mutation-positive non-small cell lung cancer. *Clin Cancer Res.* 2017;23:618-622.
75. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med.* 2018;378:113-125.
76. Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. *Nature Med.* 2018;24:638-646.
77. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med.* 2005;2:e73.
78. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med.* 2011;3:75ra26.
79. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc Natl Acad Sci U S A.* 2008;105:2070-2075.
80. Yoshikawa S, Kukimoto-Niino M, Parker L, et al. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. *Oncogene.* 2013;32:27-38.
81. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. *Science.* 1994;263:1281-1284.
82. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell.* 2007;131:1190-1203.

83. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. *Cancer Sci.* 2008;99:2349-2355.
84. Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M. Anaplastic lymphoma kinase: role in specific tumors, and development of small molecule inhibitors for cancer therapy. *Cancer Lett.* 2010;299:81-94.
85. Melosky B, Cheema P, Agulnik J, et al. Canadian perspectives: update on inhibition of ALK-positive tumors in advanced non-small-cell lung cancer. *Curr Oncol.* 2018;25:317-328.
86. Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. *Cancer Discov.* 2017;7:596-609.
87. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Inter-group (IFCT). *Lancet.* 2016;387:1415-1426.
88. Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. *JAMA Oncol.* 2016;2:313-320.
89. Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. *J Thorac Oncol.* 2015;10:768-777.
90. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. *Oncogene.* 2000;19:5548-5557.
91. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the *ROS1* gene in human glioblastoma cells. *Proc Natl Acad Sci U S A.* 1987;84:9270-9274.
92. Charest A, Lane K, McMahon K, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). *Genes Chromosomes Cancer.* 2003;37:58-71.
93. Bergethson K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol.* 2012;30:863-870.
94. Zhu Q, Zhan P, Zhang X, Lv T, Song Y. Clinicopathologic characteristics of patients with *ROS1* fusion gene in non-small cell lung cancer: a meta-analysis. *Transl Lung Cancer Res.* 2015;4:300-309.
95. Mazieres J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. *J Clin Oncol.* 2015;33:992-999.
96. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med.* 2014;371:1963-1971.
97. Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. *Am J Surg Pathol.* 2013;37:554-562.
98. Zhou J, Zhao J, Zheng J, et al. A prediction model for ROS1-rearranged lung adenocarcinomas based on histologic features. *PLoS One.* 2016;11:e0161861.
99. Zhao J, Zheng J, Kong M, Zhou J, Ding W, Zhou J. Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell. *Oncotarget.* 2016;7:74162-74170.
100. Ju L, Han M, Su J, Wu C, Dong Z. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib. *Cancer Chemother Pharmacol.* 2018;82:561-564.
101. Lou G, Yu X, Song Z. Molecular profiling and survival of completely resected primary pulmonary neuroendocrine carcinoma. *Clin Lung Cancer.* 2017;18:e197-e201.
102. Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF alterations as therapeutic targets in non-small-cell lung cancer. *J Thorac Oncol.* 2015;10:1396-1403.
103. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. *Oncogene.* 2018;37:3183-3199.
104. Yao Z, Torres NM, Tao A, et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. *Cancer Cell.* 2015;28:370-383.
105. Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumors with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. *Nature.* 2017;548:234-238.

106. Baik CS, Myall NJ, Wakelee HA. Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy. *Oncologist*. 2017;22:786-796.
107. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol*. 2017;18:1307-1316.
108. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat Rev Neurosci*. 2003;4:299-309.
109. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. *Nature*. 1991;350:158-160.
110. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. *Cancer Discov*. 2015;5:25-34.
111. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumor types. *ESMO Open*. 2016;1:e000023.
112. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. *Nature Med*. 2013;19:1469-1472.
113. Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion [e-pub ahead of print]. *JCO Precis Oncol*. doi: 10.1200/PO.18.00037, accessed July 23, 2018.
114. Scott LJ. Larotrectinib: first global approval. *Drugs*. 2019;79:201-206.
115. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumors: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020;21:271-282.
116. Park M, Dean M, Cooper CS, et al. Mechanism of met oncogene activation. *Cell*. 1986;45:895-904.
117. Bottaro DP, Rubin JS, Falletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science*. 1991;251:802-804.
118. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. *EMBO J*. 1991;10:2867-2878.
119. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. *Nat Rev Mol Cell Biol*. 2010;11:834-848.
120. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. *Ther Adv Med Oncol*. 2011;3:S7-S19.
121. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. *J Clin Oncol*. 2009;27:1667-1674.
122. Dziadziuszko R, Wynes MW, Singh S, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. *J Thorac Oncol*. 2012;7:340-347.
123. Park S, Koh J, Kim DW, et al. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. *Lung Cancer*. 2015;90:381-387.
124. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. *Br J Cancer*. 2019;121:725-737.
125. Lai GGY, Lim TH, Lim J, et al. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer. *J Clin Oncol*. 2019;37:876-884.
126. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014;511:543-550.
127. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. *Cancer Discov*. 2015;5:850-859.
128. Reungwetwattana T, Liang Y, Zhu V, Ou SI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. *Lung Cancer*. 2017;103:27-37.

129. Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. *J Clin Oncol.* 2016;34:721-730.
130. Zheng D, Wang R, Ye T, et al. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. *Oncotarget.* 2016;7:41691-41702.
131. Heist RS, Shim HS, Gingipally S, et al. MET exon 14 skipping in non-small cell lung cancer. *Oncologist.* 2016;21:481-486.
132. Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer: a systematic review and meta-analysis. *Lung Cancer.* 2018;123:76-82.
133. Planchard D. Have we really MET a new target? [e-pub ahead of print]. *J Clin Oncol.* doi:10.1200/JCO.2018.79.3455, accessed September 25, 2018.
134. Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in lung cancer: will expectations finally be MET? *J Thorac Oncol.* 2017;12:15-26.
135. Takeuchi K. Discovery stories of RET fusions in lung cancer: a mini-review. *Front Physiol.* 2019;10:216.
136. Iams WT, Lovly CM. Stop fRETting the target: next-generation RET inhibitors have arrived. *Cancer Discov.* 2018;8:797-799.
137. Tsuta K, Kohno T, Yoshida A, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. *Br J Cancer.* 2014;110:1571-1578.
138. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. *Clin Cancer Res.* 2017;23:1988-1997.
139. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. *Nature Med.* 2012;18:375-377.
140. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nature Med.* 2012;18:382-384.
141. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nature Med.* 2012;18:378-381.
142. Michels S, Scheel AH, Scheffler M, et al. Clinicopathological characteristics of RET rearranged lung cancer in European patients. *J Thorac Oncol.* 2016;11:122-127.
143. Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. *J Clin Oncol.* 2012;30:4352-4359.
144. Dugay F, Llamas-Gutierrez F, Gournay M, et al. Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. *Oncotarget.* 2017;8:53336-53351.
145. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving pre-clinical and clinical landscapes. *Nat Rev Clin Oncol.* 2018;15:150.
146. Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-art strategies for targeting RET-dependent cancers. *J Clin Oncol.* 2020;38:1209-1221.
147. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. *Cell.* 2017;170:17-33.
148. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. *Clin Lung Cancer.* 2006;8:30-38.
149. Yang H, Liang SQ, Schmid RA, Peng RW. New horizons in KRAS-mutant lung cancer: dawn after darkness. *Front Oncol.* 2019;9:953.
150. Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. *Lung Cancer.* 2016;102:122-134.
151. Ding Y, Zhang L, Guo L, et al. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients. *Thorac Cancer.* 2020;11:103-112.
152. Jiang L, Mino-Kenudson M, Roden AC, et al. Association between the novel classification of lung

- adenocarcinoma subtypes and EGFR/KRAS mutation status: a systematic literature review and pooled-data analysis. *Eur J Surg Oncol.* 2019;45:870-876.
153. McCormick F. Sticking it to KRAS: covalent inhibitors enter the clinic. *Cancer Cell.* 2020;37:3-4.
 154. Lanman BA, Allen JR, Allen JG, et al. Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. *J Med Chem.* 2020;63:52-65.
 155. Koga T, Kobayashi Y, Tomizawa K, et al. Activity of a novel HER2 inhibitor, poztotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: an in vitro study. *Lung Cancer.* 2018;126:72-79.
 156. Nagasaka M, Ou SI. Neuregulin 1 fusion-positive NSCLC. *J Thorac Oncol.* 2019;14:1354-1359.
 157. Pan Y, Zhang Y, Ye T, et al. Detection of novel NRG1, EGFR, and MET fusions in lung adenocarcinomas in the Chinese population. *J Thorac Oncol.* 2019;14:2003-2008.
 158. Trombetta D, Graziano P, Scarpa A, et al. Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. *Oncotarget.* 2018;9:9661-9671.
 159. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer.* 2012;12:252-264.
 160. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell.* 2015;27:450-461.
 161. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science.* 2018;359:1350-1355.
 162. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. *Nature.* 2017;541:321-330.
 163. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science.* 2015;348:124-128.
 164. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet.* 2019;51:202-206.
 165. Buttner R, Gosney JR, Skov BG, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. *J Clin Oncol.* 2017;35:3867-3876.
 166. Dafni U, Tsourtis Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. *Lung Cancer.* 2019;134:127-140.
 167. Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. *Medicine (Baltimore).* 2018;97:e11936.
 168. Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee. *J Thorac Oncol.* 2020;15:499-519.
 169. Melosky B, Chu Q, Juergens RA, et al. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. *Cancer Treat Rev.* 2018;65:65-77.
 170. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *J Thorac Oncol.* 2013;8:823-859.
 171. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. *J Clin Oncol.* 2014;32:3673-3679.
 172. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Thorac Oncol.* 2018;13:323-358.

173. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. *J Clin Oncol*. 2018;36:911-919.
174. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. *Clin Cancer Res*. 2007;13:4954-4955. doi:13/17/4954 [pii] 10.1158/1078-0432.CCR-07-1387 (2007).
175. Young EC, Owens MM, Adebisi I, et al. A comparison of methods for EGFR mutation testing in non-small cell lung cancer. *Diagn Mol Pathol*. 2013;22:190-195.
176. Cheung CC, Garratt J, Won J, et al. Developing ALK immunohistochemistry and in situ hybridization proficiency testing for non-small cell lung cancer in Canada: Canadian immunohistochemistry quality control challenges and successes. *Appl Immunohistochem Mol Morphol*. 2015;23:677-681.
177. Cutz JC, Craddock KJ, Torlakovic E, et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. *J Thorac Oncol*. 2014;9:1255-1263.
178. Whitcombe D, Theaker J, Guy SP, Brown T, Little S. Detection of PCR products using self-probing amplicons and fluorescence. *Nat Biotechnol*. 1999;17:804-807.
179. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. *Clin Cancer Res*. 2006;12:3915-3921.
180. Won JK, Keam B, Koh J, et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. *Ann Oncol*. 2015;26:348-354.
181. Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively parallel sequencing of 12 human exomes. *Nature*. 2009;461:272-276.
182. Remon J, Caramella C, Jovelet C, et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumor DNA. *Ann Oncol*. 2017;28:784-790.
183. Vogelstein B, Kinzler KW. Digital PCR. *Proc Natl Acad Sci U S A*. 1999;96:9236-9241.
184. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. *Anal Chem*. 2011;83:8604-8610.
185. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. *Proc Natl Acad Sci U S A*. 2003;100:8817-8822.
186. Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. *J Clin Oncol*. 2016;34:3375-3382.
187. Peters S, Dafni U, Boyer M, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). *Ann Oncol*. 2019;30:161-165.
188. Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. *Ann Oncol*. 2018;29:i20-i27.
189. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. *J Thorac Oncol*. 2018;13:1248-1268.
190. Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. *J Clin Oncol*. 2018;36:1631-1641.
191. Passiglia F, Rizzo S, Di Maio M, et al. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. *Sci Rep*. 2018;8:13379.

192. Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. *Ann Oncol*. 2015;26:1415-1421.
193. Cheema PK, Menjak IB, Winterton-Perks Z, et al. Impact of reflex EGFR/ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer. *J Oncol Pract*. 2017;13:e130-e138.
194. Lim C, Sekhon HS, Cutz JC, et al. Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario. *Curr Oncol*. 2017;24:103-110.

第4章 肺癌治疗的外科思考

1. *Lung and Bronchus Cancer—Cancer Stat Facts*. Available at: <https://seer.cancer.gov/statfacts/html/lungb.html>. Accessed October 13, 2019.
2. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. Lung cancer stage classification. *Chest*. 2017;151(1):193-203.
3. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. *J Thorac Oncol*. 2007;2(8):706-714.
4. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer—diagnosis and management of lung cancer. *Chest*. 2013;143(5):211-250.
5. Darling GE, Maziak DE, Inculet RI, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. *J Thorac Oncol*. 2011;6(8):1367-1372.
6. Arias S, Yarmus L, Argento AC. Navigational transbronchial needle aspiration, percutaneous needle aspiration and its future. *J Thorac Dis*. 2015;7:S317-S328.
7. Wood DE, Chair V, Aggarwal C, et al. *Non-Small Cell Lung Cancer NCCN Evidence Blocks*. NCCN; 2019.
8. Bille A, Woo KM, Ahmad U, Rizk NP, Jones DR. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. *Eur J Cardiothorac Surg*. 2017;51(4):674-679.
9. Seder CW, Wright CD, Chang AC, Han JM, McDonald D, Kozower BD. The Society of thoracic surgeons general thoracic surgery database update on outcomes and quality. *Ann Thorac Surg*. 2016;101:1646-1654.
10. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(suppl 5):e166S-e190S.
11. Fernandez FG, Kosinski AS, Burfeind W, et al. The Society of Thoracic Surgeons lung cancer resection risk model: higher quality data and superior outcomes. In: *Annals of Thoracic Surgery*. Vol 102. Philadelphia, PA: Elsevier USA; 2016:370-377.
12. Licker MJ, Widikker I, Robert J, et al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. *Ann Thorac Surg*. 2006;81(5):1830-1837.
13. Ferguson MK, Siddique J, Karrison T. Modeling major lung resection outcomes using classification trees and multiple imputation techniques. *Eur J Cardiothorac Surg*. 2008;34(5):1085-1089.
14. British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. Guidelines on the selection of patients with lung cancer for surgery. *Thorax*. 2001;56(2):89-108.
15. Ferguson MK, Vigneswaran WT. Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease. *Ann Thorac Surg*. 2008;85(4):1158-1165.
16. Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. *Ann Thorac Surg*. 2003;76(6):1782-1788.
17. Bagan P, Berna P, Pereira JCDN, et al. Sleeve lobectomy versus pneumonectomy: tumor characteristics and comparative analysis of feasibility and results. *Ann Thorac Surg*. 2005;80(6):2046-2050.
18. Pagès P-B, Mordant P, Renaud S, et al. Sleeve lobectomy may provide better outcomes than pneumonectomy for non-small cell lung cancer. A decade in a nationwide study. *J Thorac Cardiovasc Surg*. 2017;153(1):184-195.e3.
19. Milman S, Kim AW, Warren WH, et al. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. *Ann Thorac Surg*. 2009;88(3):945-950.

20. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. *Ann Thorac Surg.* 2005;80(6):2051-2056.
21. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. *Eur J Cardiothorac Surg.* 2006;30(5):787-792.
22. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. *J Thorac Cardiovasc Surg.* 2011;141(3):662-670.
23. Keller SM, Adak S, Wagner H, Johnson DH. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. *Ann Thorac Surg.* 2000;70(2):358-365.
24. Swanson SJ, Meyers BF, Gunnarsson CL, et al. Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multiinstitutional database analysis. *Ann Thorac Surg.* 2012;93(4):1027-1032.
25. Long H, Tan Q, Luo Q, et al. Thoracoscopic surgery versus thoracotomy for lung cancer: short-term outcomes of a randomized trial. *Ann Thorac Surg.* 2018;105(2):386-392.
26. Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. *J Thorac Cardiovasc Surg.* 2010;139(4):976-983.
27. Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. *Lancet Oncol.* 2016;17(6):836-844.
28. Reddy RM, Gorrepati ML, Oh DS, Mehendale S, Reed MF. Robotic-assisted versus thoracoscopic lobectomy outcomes from high-volume thoracic surgeons. *Ann Thorac Surg.* 2018;106(3):902-908.
29. Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS) Society and the European Society of Thoracic Surgeons (ESTS). *Eur J Cardiothorac Surg.* 2019;55(1):91-115.
30. Van Haren RM, Mehran RJ, Mena GE, et al. Enhanced recovery decreases pulmonary and cardiac complications after thoracotomy for lung cancer. *Ann Thorac Surg.* 2018;106(1):272-279.
31. David EA, Andersen SW, Beckett LA, et al. Survival benefits associated with surgery for advanced non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 2019;157(4):1620-1628.
32. Detterbeck FC, Chansky K, Groome P, et al. The IASLC Lung Cancer Staging Project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (eighth) edition of the TNM classification of lung cancer. *J Thorac Oncol.* 2016;11(9):1433-1446.
33. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. *Ann Thorac Surg.* 1995;60(3):615-623.
34. Wolf AS, Richards WG, Jaklitsch MT, et al. Lobectomy versus sublobar resection for small (2 cm or Less) nonsmall cell lung cancers. *Ann Thorac Surg.* 2011;92(5):1819-1825.
35. Kodama K, Higashiyama M, Okami J, et al. Oncologic outcomes of segmentectomy versus lobectomy for clinical T1a N0 M0 non-small cell lung cancer. *Ann Thorac Surg.* 2016;101(2):504-511.
36. Taioli E, Yip R, Olkin I, et al. Survival after sublobar resection for early-stage lung cancer: methodological obstacles in comparing the efficacy to lobectomy. *J Thorac Oncol.* 2016;11(3):400-406.
37. Bao F, Ye P, Yang Y, et al. Segmentectomy or lobectomy for early stage lung cancer: a meta-analysis. *Eur J Cardiothorac Surg.* 2014;46(1):1-7.
38. Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. *Lancet.* 2022;399(10335):1607-1617.
39. Altorki N, Wang X, Kozono D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. *N Engl J Med.* 2023;388(6):489-498.
40. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. *Cancer.* 2009;115(22):5218-5227.

41. Lüchtenborg M, Riaz SP, Coupland VH, et al. High procedure volume is strongly associated with improved survival after lung cancer surgery. *J Clin Oncol.* 2013;31(25):3141-3146.
42. Doddoli C, D'Journo B, Le Pimpec-Barthes F, et al. Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. *Ann Thorac Surg.* 2005;80(6):2032-2040.
43. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). *J Clin Oncol.* 2007;25(3):313-318.
44. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II Study 8805. *J Clin Oncol.* 1995;13(8):1880-1892.
45. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. *J Clin Oncol.* 2000;18(16):2981-2989.
46. Pless M, Stupp R, Ris HB, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. *Lancet.* 2015;386(9998):1049-1056.
47. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet.* 2009;374(9687):379-386.
48. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. *J Natl Cancer Inst.* 2007;99(6):442-450.
49. Stefani A, Alifano M, Bobbio A, et al. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. *J Thorac Cardiovasc Surg.* 2010;140(2):356-363.
50. Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. *Ann Thorac Surg.* 2008;86(2):362-366.
51. De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). *J Thorac Oncol.* 2012;7(10):1547-1555.
52. Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet Oncol.* 2016;17(12):1672-1682.
53. Stephens SJ, Moravan MJ, Salama JK. Managing patients with oligometastatic non-small-cell lung cancer. *J Oncol Pract.* 2018;14(1):23-31.
54. Sheu T, Heymach JV, Swisher SG, et al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. *Int J Radiat Oncol Biol Phys.* 2014;90(4):850-857.
55. Raz DJ, Lanuti M, Gaissert HC, Wright CD, Mathisen DJ, Wain JC. Outcomes of patients with isolated adrenal metastasis from non-small cell lung Carcinoma. *Ann Thorac Surg.* 2011;92(5):1788-1793.
56. Mercier O, Fadel E, De Perrot M, et al. Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 2005;130(1):136-140.
57. Ni Y, Ye X, Yang X, et al. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment. *J Cancer Res Clin Oncol.* 2020;46:197-203.
58. Wang Z, Gao S-G, Xue Q, et al. Surgery of primary non-small cell lung cancer with oligometastasis: analysis of 172 cases. *J Thorac Dis.* 2018;10(12):6540-6546.
59. Ning MS, Gomez DR, Heymach JV, Swisher SG. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. *Transl Lung Cancer Res.* 2019;8(1):97-106.
60. Wakeam E, Acuna SA, Leighl NB, et al. Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival. *Lung Cancer.* 2017;109:78-88.

第5章 可切除肺癌

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(1):7-30.
2. Mathisen DJ. Is video-assisted thoracoscopic lobectomy inferior to open lobectomy oncologically? *Ann Thorac Surg*. 2013;96(3):755-756.
3. Boffa DJ, Kosinski AS, Paul S, Mitchell JD, Onaitis M, et al. Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. *Ann Thorac Surg*. 2012;94(2):347-353.
4. Licht PB, Jørgensen OD, Ladegaard L, Jakobsen E. A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer. *Ann Thorac Surg*. 2013;96(3):943-950.
5. Boffa DJ, Kosinski AS, Furnary AP, Kim S, Onaitis MW, Tong BC. Minimally invasive lung cancer surgery performed by thoracic surgeons as effective as thoracotomy. *J Clin Oncol*. 2018;36(23):2378-2385.
6. Liu L, Zhang LJ, Chen B, Cao JM, Lu GM, Yuan L, et al. Novel CT-guided coil localization of peripheral pulmonary nodules prior to video-assisted thoracoscopic surgery: a pilot study. *Acta Radiol*. 2014;55(6):699-706.
7. McGuire AL, Vieira A, Grant K, Mayo J, Sedlic T, Choi J, et al. Computed tomography-guided platinum microcoil lung surgery: a cross-sectional study. *J Thorac Cardiovasc Surg*. 2019;158(2):594-600.
8. Khoreba M, Ferraro P, Duranceau A, Martin J, Goudie E, Thiffault V, et al. Thoracoscopic localization of intraparenchymal pulmonary nodules using direct intracavitary thoracoscopic ultrasonography prevents conversion of VATS procedures to thoracotomy in selected patients. *J Thorac Cardiovasc Surg*. 2012;144(5):1160-1166.
9. Ujiie H, Kato T, Hu H-P, Hasan S, Patel P, Wada H, et al. Evaluation of a new ultrasound thoracoscope for localization of lung nodules in ex vivo human lungs. *Ann Thorac Surg*. 2017;103(3):926-934.
10. Sharma A, McDermott S, Mathisen DJ, Shepard J-AO, et al. Preoperative localization of lung nodules with fiducial markers: feasibility and technical considerations. *Ann Thorac Surg*. 2017;103(4):1114-1120.
11. Qi H, Wan C, Zhang L, Wang J, Song Z, Zhang R, et al. Early effective treatment of small pulmonary nodules with video-assisted thoracoscopic surgery combined with CT-guided dual-barbed hookwire localization. *Oncotarget*. 2017;8(24):38793.
12. Hachey KJ, Digesu CS, Armstrong KW, Gilmore DM, Khullar OV, Whang B, et al. A novel technique for tumor localization and targeted lymphatic mapping in early-stage lung cancer. *J Thorac Cardiovasc Surg*. 2017;154(3):1110-1118.
13. Fu Y-F, Zhang M, Wu W-B, Wang T, et al. Coil localization-guided video-assisted thoracoscopic surgery for lung nodules. *J Laparoendosc Adv Surg Tech A*. 2018;28(3):292-297.
14. Kleedehn M, Kim DH, Lee FT, Lubner MG, Robbins JB, Ziemlewicz TJ, et al. Preoperative pulmonary nodule localization: a comparison of methylene blue and hookwire techniques. *AJR Am J Roentgenol*. 2016;207(6):1334-1339.
15. Predina JD, Okusanya O, Newton AD, Low P, Singhal S, et al. Standardization and optimization of intraoperative molecular imaging for identifying primary pulmonary adenocarcinomas. *Mol Imaging Biol*. 2018;20(1):131-138.
16. Willekes L, Boutros C, Goldfarb MA. VATS intraoperative tattooing to facilitate solitary pulmonary nodule resection. *J Cardiothorac Surg*. 2008;3(1):13.
17. Donington JS, Kim YT, Tong B, Moreira AL, Bessich J, Weiss KD, et al. Progress in the management of early-stage non-small cell lung cancer in 2017. *J Thorac Oncol*. 2018;13(6):767-778.
18. Wei B, Abraham P. Commentary: will it go platinum? Microcoil localization as an adjunct to thoracoscopic wedge resection. *J Thorac Cardiovasc Surg*. 2019;158(2):603.
19. Subramanian MP, Puri V. Commentary: I saw, therefore I coiled—solving the small nodule problem. *J Thorac Cardiovasc Surg*. 2019;158(2):601-602.

20. Ginsberg RJ, Rubinstein LV, Group LCS. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. *Ann Thorac Surg.* 1995;60(3):615-623.
21. El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. *Ann Thorac Surg.* 2006;82(2):408-416.
22. Okami J, Ito Y, Higashiyama M, Nakayama T, Tokunaga T, Maeda J, et al. Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. *Ann Thorac Surg.* 2010; 90(5):1651-1656.
23. Kamel MK, Rahouma M, Lee B, Harrison SW, Stiles BM, Altorki NK, et al. Segmentectomy is equivalent to lobectomy in hypermetabolic clinical stage IA lung adenocarcinomas. *Ann Thorac Surg.* 2019;107(1):217-223.
24. Koike T, Kitahara A, Sato S, Hashimoto T, Aoki T, Koike T, et al. Lobectomy versus segmentectomy in radiologically pure solid small-sized non-small cell lung cancer. *Ann Thorac Surg.* 2016;101(4):1354-1360.
25. Koike T, Yamato Y, Yoshiya K, Shimoyama T, Suzuki R, et al. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. *J Thorac Cardiovasc Surg.* 2003;125(4):924-928.
26. Altorki NK, Wang X, Wigle D, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). *Lancet Respir Med.* 2018;6(12):915-924.
27. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol.* 2016;11(1):39-51.
28. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer. *NE J Med.* 2023;338(6):489-498.
29. Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. *The Lancet.* 2022;399(10335):1607-1617.
30. Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. *J Thorac Oncol.* 2015;10(12):1675-1684.
31. Osarogiabon RU, Smeltzer MP, Faris N, Rami-Porta R, Goldstraw P, Asamura H, et al. Comment on the proposals for the revision of the N descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. *J Thorac Oncol.* 2016;11(10):1612-1614.
32. Heineman DJ, Ten Berge MG, Daniels JM, Versteegh MI, Marang-van de Mheen PJ, Wouters MW, et al. Clinical staging of stage I non-small cell lung cancer in The Netherlands—need for improvement in an era with expanding nonsurgical treatment options: data from the Dutch Lung Surgery Audit. *Ann Thorac Surg.* 2016;102(5):1615-1621.
33. Heineman DJ, Ten Berge MG, Daniels JM, Versteegh MI, Marang-van de Mheen PJ, Wouters MW, et al. The quality of staging non-small cell lung cancer in The Netherlands: data from the Dutch Lung Surgery Audit. *Ann Thorac Surg.* 2016;102(5):1622-1629.
34. David EA, Cooke DT, Chen Y, Nijar K, Canter RJ, Cress RD, et al. Does lymph node count influence survival in surgically resected non-small cell lung cancer? *Ann Thorac Surg.* 2017;103(1):226-235.
35. Liang W, He J, Shen Y, He Q, Zhang J, et al. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER Database and a Chinese Multi-Institutional Registry. *J Clin Oncol.* 2017;35(11):1162-1170.
36. Krantz SB, Lutfi W, Kuchta K, Wang CH, Kim KW, Howington JA, et al. Improved lymph node staging in early-stage lung cancer in the National Cancer Database. *Ann Thorac Surg.* 2017;104(6):1805-1814.
37. Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abaira V, i Figuls MR, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. *Cochrane Database Syst Rev.* 2014;2014(11):CD009519.

38. De Leyn P, Doooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. *Eur J Cardiothorac Surg.* 2014;45(5):787-798.
39. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2013;143(5):e211S-e250S.
40. Darling GE, Dickie AJ, Malthaner RA, Kennedy E, Tey R, et al. Invasive mediastinal staging of non-small-cell lung cancer: a clinical practice guideline. *Curr Oncol.* 2011;18(6):e304-e310.
41. Bendzsak A, Waddell TK, Yasufuku K, Keshavjee S, de Perrot M, Cypel M, et al. Invasive mediastinal staging guideline concordance. *Ann Thorac Surg.* 2017;103(6):1736-1741.
42. Osarogiagbon RU, Lee Y-S, Faris NR, Ray MA, Ojeabulu PO, Smeltzer MP, et al. Invasive mediastinal staging for resected non-small cell lung cancer in a population-based cohort. *J Thorac Cardiovasc Surg.* 2019;158(4):1220-1229.e2.
43. Thornblade LW, Wood DE, Mulligan MS, Farivar AS, Hubka M, Costas KE, et al. Variability in invasive mediastinal staging for lung cancer: a multicenter regional study. *J Thorac Cardiovasc Surg.* 2018;155(6):2658-2671.
44. Vyas KS, Davenport DL, Ferraris VA, Saha SP, et al. Mediastinoscopy: trends and practice patterns in the United States. *South Med J.* 2013;106(10):539.
45. Osarogiagbon RU, Darling GE. Towards optimal pathologic staging of resectable non-small cell lung cancer. *Transl Lung Cancer Res.* 2013;2(5):364-371.
46. Osarogiagbon RU, Lee Y-S, Faris NR, Ray MA, Ojeabulu PO, Smeltzer MP. Invasive mediastinal staging for resected non-small cell lung cancer in a population-based cohort. *J Thorac Cardiovasc Surg.* 2019.
47. Miller RJ, Mudambi L, Vial MR, Hernandez M, Eapen GA, et al. Evaluation of appropriate mediastinal staging among endobronchial ultrasound bronchoscopists. *Ann Am Thorac Soc.* 2017;14(7):1162-1168.
48. Smeltzer MP, Lee Y, Faris NR, Ray MA, Fehnel C, Houston-Harris C, et al. Thoroughness of staging and the outcomes of surgical resection outcomes in potentially curable non-small cell lung cancer. Paper presented at: IASLC 18th World Conference on Lung Cancer 2017; Yokohama, Japan.
49. Mokhles S, Macbeth F, Treasure T, Younes RN, Rintoul RC, Fiorentino F, et al. Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis. *Eur J Cardiothorac Surg.* 2017;51(6):1149-1156.
50. Wang Y, Darling GE. Complete mediastinal lymph node dissection versus systematic lymph node sampling in surgical treatment of non-small cell lung cancer: do we have the answer? *J Thorac Dis.* 2017;9(11):4169.
51. Zhang J, Mao T, Gu Z, Guo X, Chen W, Fang W, et al. Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: results of a prospective randomized trial. *Thorac Cancer.* 2013;4(4):416-421.
52. Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. *J Thorac Cardiovasc Surg.* 2011;141(3):662-670.
53. Smeltzer MP, Faris NR, Ray MA, et al. Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent. *JAMA Oncol.* 2018;4:80-87.
54. Choe G, Schipper P. Quality of lymph node assessment and survival among patients with non-small cell lung cancer. *JAMA Oncol.* 2018;4:1-2.
55. Osarogiagbon RU, Ray MA, Faris NR, Smeltzer MP, Fehnel C, Houston-Harris C, et al. Prognostic value of national comprehensive cancer network lung cancer resection quality criteria. *Ann Thorac Surg.* 2017;103(5):1557-1565.
56. Lin CC, Smeltzer MP, Jemal A, Osarogiagbon RU, et al. Risk-adjusted margin positivity rate as a surgical quality metric for non-small cell lung cancer. *Ann Thorac Surg.* 2017;104(4):1161-1170.
57. Katz MH, Francescatti AB, Hunt KK, Surgeons CSSPotACo. Technical standards for cancer surgery:

- Commission on Cancer Standards 5.3–5.8. *Ann Surg Oncol*. 2022;29(11):6549–6558.
58. Facciolo F, Cardillo G, Lopergolo M, Pallone G, Sera F, Martelli M. Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection. *J Thorac Cardiovasc Surg*. 2001;121(4):649–656.
 59. Donington JS. Chest wall resections. In: Evans SRT, editor. *Surgical Pitfalls*. Philadelphia: W.B. Saunders;2009:705–716.
 60. Chang WJ, Sun J-M, Lee JY, Ahn JS, Ahn M-J, Park KA, et al. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. *Lung Cancer*. 2014;84(1):51–55.
 61. Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol*. 2008;26(21):3552–3559.
 62. Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. *Cochrane Database Syst Rev*. 2015;(3):CD011430.
 63. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2017;18(12):1610–1623.
 64. Felip E, Altorki N, Zhou C, Csősz T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. *The Lancet*. 2021;398(10308):1344–1357.
 65. Wu Y-L, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. *NE J Med*. 2020;383(18):1711–1723.
 66. Detterbeck F. What to do with “surprise” N2?: intraoperative management of patients with non-small cell lung cancer. *J Thorac Oncol*. 2008;3(3):289–302.
 67. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2013;143(5, Supplement):e314S–e340S.
 68. Donington JS. Chest wall resections. In: Evans SRT, ed. *Surgical Pitfalls*. Philadelphia: WB Saunders; 2009:705–716.
 69. Bryan DS, Donington JS. The role of surgery in management of locally advanced non-small cell lung cancer. *Curr Treat Options Oncol*. 2019;20(4):27.
 70. Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. *The Lancet*. 2014;383(9928):1561–1571.
 71. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam Jr J, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. *J Natl Cancer Inst*. 1994;86(9):673–680.
 72. Rosell R, Maestre J, Font A, Moreno I, Molina F, Milla A, et al. A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer. Paper presented at Seminars of Oncology 1994.
 73. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. *Ann Thorac Surg*. 1992;53(6):992–998.
 74. Pless M, Stupp R, Ris H-B, Stahel RA, Weder W, Thierstein et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. *Lancet*. 2015;386(9998):1049–1056.
 75. Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). *Cancer*. 2012;118(24):6126–6135.
 76. Girard N, Mornex F, Douillard J-Y, Bossard N, Quoix E, Beckendorf V, et al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. *Lung Cancer*. 2010;69(1):86–93.
 77. Yang CF, Gulack BC, Gu L, Speicher PJ, Wang X, Harpole DH, et al. Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2015;150(6):1484–1492.

78. Higgins K, Chino JP, Marks LB, Ready N, D'Amico TA, Clough RW et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2009;75(5):1462-1467.
79. Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, Linder A et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. *Lancet Oncol*. 2008;9(7):636-648.
80. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med*. 2017;377(20):1919-1929.
81. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med*. 2018;379(24):2342-2350.
82. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. *N Engl J Med*. 2018;378(21):1976-1986.
83. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. *NE J Med*. 2022;386(21):1973-1985.
84. Rusch VW, Chaft JE, Johnson B, Wistuba II, Kris MG, Lee JM, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): initial results from a multicenter study (LCMC3). *J Clin Oncol*. 2018;36(suppl 15):8541-8541.
85. Provencio M, Nadal E, Insa A, Campelo RG, Casal J, Domine M, et al. OA13.05 NADIM Study: updated clinical research and outcomes. *J Thorac Oncol*. 2019;14(10):S241.
86. Provencio-Pulla M., Nadal-Alforja E., Cobo M., Insa A., Costa Rivas M., Majem M., Rodriguez-Abreu D., Lopez-Vivanco G., Domine M., Del Barco Morillo E., et al. Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG. *J. Clin. Oncol*. 2018;36:8521.
87. Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. *Nat Med*. 2022;28(10):2155-2161.
88. Albain KS, Swann RS, Rusch VW, Turrisi AT, 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet*. 2009;374(9687):379-386.
89. Kim AW, Boffa DJ, Wang Z, Detterbeck FC, et al. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2012;143(1):55-63.
90. Marulli G, Battistella L, Mammana M, Calabrese F, Rea F, et al. Superior sulcus tumors (Pancoast tumors). *Ann Translat Med*. 2016;4(12):239.
91. Ginsberg RJ, Martini N, Zaman M, Armstrong JG, Bains MS, Burt ME, et al. Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. *Ann Thorac Surg*. 1994;57(6):1440-1445.
92. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *J Thorac Cardiovasc Surg*. 2001;121(3):472-483.

第6章 寡转移

1. Fernandez RAS, Lau RWH, Ho JYK, et al. Evidence for surgical resections in oligometastatic lung cancer. *J Thorac Dis.* 2019;11(1):S969-S975.
2. Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. *Clin Lung Cancer.* 2014;15(5):346-355.
3. Hanagiri T, Takenaka M, Oka S, et al. Results of a surgical resection for patients with stage IV non-small-cell lung cancer. *Clin Lung Cancer.* 2012;13(3):220-224.
4. Collaud S, Stahel R, Inci I, et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. *Lung Cancer.* 2012;78(3):234-238.
5. Tamura T, Kurishima K, Watanabe H, et al. Characteristics of clinical N0 metastatic non-small cell lung cancer. *Lung Cancer.* 2015;89(1):71-75.
6. Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for oligometastatic lung cancer. *Front Oncol.* 2017;7:210.
7. Nagata Y, Hiraoka M, Shibata T. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. *Radiat Oncol Biol.* 2015;93(5):989-996.
8. Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. *Semin Cancer Biol.* 2018;52(Pt 1):103-109.
9. Wagner H, Langer CJ. Non-small cell lung cancer. *Clin Radiat Oncol.* 2015:809-842.e8.
10. Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. *Lung Cancer.* 2012;75(1):9-14.
11. Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases a randomized clinical trial. *J Am Med Assoc.* 2016;316(4):401-409.
12. Cancer.org. *Cancer Facts and Figures 2019.* 2019. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf>.
13. Shin J, Keam B, Kim M, et al. Prognostic impact of newly proposed M descriptors in TNM classification of non-small cell lung cancer. *J Thorac Oncol.* 2017;12(3):520-528.
14. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol.* 1995;13:8-10.
15. Stephens SJ, Moravan MJ, Salama JK. Managing patients with oligometastatic non-small-cell lung cancer. *J Oncol Pract.* 2018;14(1):23-31.
16. Niiibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. *Jpn J Clin Oncol.* 2010;40(2):107-111.
17. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. *J Thorac Oncol.* 2012;7(12):1807-1814.
18. Yano T, Okamoto T, Haro A, et al. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. *Lung Cancer.* 2013;82(3):431-435.
19. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. *J Thorac Oncol.* 2016;11(1):39-51.

20. Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet Oncol.* 2016;17(12):1672-1682.
21. Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. *J Clin Oncol.* 2019;37(18):1558-1565.
22. Sastry P, Tocock A, Coonar AS. Adrenalectomy for isolated metastasis from operable non-small-cell lung cancer. *Interact Cardiovasc Thorac Surg.* 2014;18(4):495-497.
23. Li D, Zhu X, Wang H, Qiu M, Li N. Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. *J Thorac Dis.* 2017;9(2):310-317.
24. David EA, Clark JM, Cooke DT, Melnikow J, Kelly K, Canter RJ. The role of thoracic surgery in the therapeutic management of metastatic non-small cell lung cancer. *J Thorac Oncol.* 2017;12(11):1636-1645.
25. David EA, Canter RJ, Chen Y, Cooke DT, Cress RD. Surgical management of advanced non-small cell lung cancer is decreasing but is associated with improved survival. *Ann Thorac Surg.* 2016;102(4):1101-1109.
26. Uhlig J, Case MD, Blasberg JD, et al. Comparison of survival rates after a combination of local treatment and systemic therapy vs systemic therapy alone for treatment of stage IV non-small cell lung cancer. *JAMA Netw Open.* 2019;2(8):e199702.
27. Kehl BKL, Landrum MB, Kahn KL, Gray SW, Chen AB, Keating NL. Tumor board participation among physicians caring for patients with lung or colorectal cancer. *J Oncol Pract.* 2015;11(3):e267-278.
28. Tamburini N, Maniscalco P, Mazzara S, et al. Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study. *Eur J Cardiothorac Surg.* 2018;53(6):1199-1204.
29. Ouyang W, Yu J, Nuerjiang S, Li Z et al. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer. *Cancer Med.* 2019;8(10):4605-4614.
30. Klotz LV, Winter H. Surgical treatment of stage I and II non-small cell lung cancer. *Onkologe.* 2018;24(12):1009-1014.
31. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. *Lancet Oncol.* 2015;16(6):630-637.
32. Suzuki H, Yoshino I. Approach for oligometastasis in non-small cell lung cancer. *Gen Thorac Cardiovasc Surg.* 2016;64(4):192-196.
33. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. *Nat Rev Clin Oncol.* 2014;11(8):473-481.
34. Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. *J Thorac Oncol.* 2018;13(9):1383-1392.
35. Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. *JAMA Oncol.* 2019;5(9):1283-1290.
36. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med.* 2016;375(19):1823-1833.
37. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med.* 2018;378(22):2078-2092.
38. Li S, Zhu R, Li D, Li N, Zhu X. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. *J Thorac Dis.* 2018;10(6):3701-3713.
39. Parikh RB, Cronin AM, Kozono DE, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2014;89(4):880-887.

40. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med*. 1990;322(8):494-500.
41. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. *J Clin Oncol*. 2012;30(4):419-425.
42. De Rose F, Cozzi L, Navarria P, et al. Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients. *Clin Oncol*. 2016;28(1):13-20.
43. Almaghrabi MY, Supiot S, Paris F, Mahé MA, Rio E. Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. *Radiat Oncol*. 2012;7(1):1-10.
44. Raz DJ, Lanuti M, Gaissert HC, Wright CD, Mathisen DJ, Wain JC. Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. *Ann Thorac Surg*. 2011;92(5):1788-1793.
45. Chance WW, Nguyen Q-N, Mehran R, et al. Stereotactic ablative radiotherapy for adrenal gland metastases: factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. *Pract Radiat Oncol*. 2017;7(3):e195-e203.
46. Ahmed KA, Caudell JJ, El-Haddad G, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys*. 2016;95(5):1399-1404.
47. Congedo MT, Cesario A, Lococo F, et al. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. *J Thorac Cardiovasc Surg*. 2012;144(2):444-452.
48. Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. *Int J Radiat Oncol Biol Phys*. 2012;82(3):1047-1057. doi:10.1016/j.ijrobp.2011.07.020.

第7章 局部晚期非小细胞肺癌

1. Lim W, Ridge CA, Nicholson AG, Mirsadraee S. The 8(th) lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. *Quant Imaging Med Surg*. 2018;8(7):709-718.
2. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol*. 2015;16(2):187-199.
3. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med*. 2018;379(24):2342-2350.
4. Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. *J Clin Oncol*. 2020;38(7):706-714.
5. Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. *J Clin Oncol*. 2015;33(18):2100-2105.
6. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. *N Engl J Med*. 1994;330(3):153-158.
7. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. *J Natl Cancer Inst*. 1994;86(9):673-680.
8. Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. *Lancet Oncol*. 2008;9(7):636-648.
9. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet*. 2009;374(9687):379-386.
10. Pechoux CL, Pourel N, Barlesi F, Lerouge D et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): a open-label, randomised, phase 3 trial. *The Lancet*. 2021; 23(1):104-114.
11. Kwong KF, Edelman MJ, Suntharalingam M, et al. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. *J Thorac Cardiovasc Surg*. 2005;129(6):1250-1257.
12. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *J Clin Oncol*. 2007;25(3):313-318.
13. Kunitoh H, Kato H, Tsuboi M, et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. *J Clin Oncol*. 2008;26(4):644-649.
14. Robinson LA, Tanvetyanon T, Grubbs D, et al. Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer. *Lung Cancer*. 2018;122:206-213.
15. Roswit B, Patno ME, Rapp R, et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. *Radiology*. 1968;90(4):688-697.
16. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with

- unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. *Cancer*. 1987;59(11):1874-1881.
17. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. *J Clin Oncol*. 2008;26(15):2457-2463.
 18. Bradley JD, Moughan J, Graham MV, et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. *Int J Radiat Oncol Biol Phys*. 2010;77(2):367-372.
 19. Schild SE, Hillman SL, Tan AD, et al. Long-term results of a trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer: NCCTG N0028 (Alliance). *J Thorac Oncol*. 2017;12(4):697-703.
 20. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys*. 2010;76(suppl 3):S70-S76.
 21. Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. *J Clin Oncol*. 2017;35(13):1387-1394.
 22. Boyle J, Ackerson B, Gu L, Kelsey CR. Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer. *Adv Radiat Oncol*. 2017;2(1):6-11.
 23. Brower JV, Amini A, Chen S, et al. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. *Ann Oncol*. 2016;27(10):1887-1894.
 24. Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. *Am J Clin Oncol*. 2007;30(3):239-244.
 25. Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. *J Clin Oncol*. 2007;25(35):5557-5561.
 26. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. *Int J Radiat Oncol Biol Phys*. 2000;48(4):1015-1024.
 27. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. *J Clin Oncol*. 2017;35(1):56-62.
 28. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. *Int J Radiat Oncol Biol Physics*. 2013;85(2):444-450.
 29. Barriger RB, Fakiris AJ, Hanna N, Yu M, Mantravadi P, McGarry RC. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatin and etoposide with or without consolidation docetaxel. *Int J Radiat Oncol Biol Phys*. 2010;78(5):1381-1386.
 30. Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. *J Clin Oncol*. 2018;36(18):1813-1822.
 31. Henke LE, Olsen JR, Contreras JA, et al. Stereotactic MR-guided online Adaptive Radiation Therapy (SMART) for ultracentral thorax malignancies: results of a phase 1 trial. *Adv Radiat Oncol*. 2019;4(1):201-209.
 32. Westover KD, Loo BW Jr, Gerber DE, et al. Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: phase 1 dose escalation trial. *Int J Radiat Oncol Biol Phys*. 2015;93(1):72-81.
 33. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. *N Engl J Med*. 1990;323(14):940-945.
 34. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. *J Natl Cancer Inst*. 1996;88(17):1210-1215.

35. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. *Chest*. 2000;117(2):358-364.
36. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. *J Clin Oncol*. 1999;17(9):2692-2699.
37. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst*. 2011;103(19):1452-1460.
38. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol*. 2010;28(13):2181-2190.
39. Vokes EE, Herndon JE II, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: cancer and leukemia group B. *J Clin Oncol*. 2007;25(13):1698-1704.
40. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. *BMJ*. 1995;311(7010):899-909.
41. Albain KS, Crowley JJ, Turrisi AT III, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. *J Clin Oncol*. 2002;20(16):3454-3460.
42. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. *J Clin Oncol*. 2005;23(25):5883-5891.
43. Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol*. 2016;34(9):953-962.
44. Santana-Davila R, Devisetty K, Szabo A, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. *J Clin Oncol*. 2015;33(6):567-574.
45. Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. *Ann Oncol*. 2017;28(4):777-783.
46. Bielopolski D, Evron E, Moreh-Rahav O, Landes M, Stemmer SM, Salamon F. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. *J Chemother*. 2017;29(2):113-117.
47. Sandler A, Ettinger DS. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. *Oncologist*. 1999;4(3):241-251.
48. Kerner GS, van Dullemen LF, Wiegman EM, et al. Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer. *Radiat Oncol*. 2014;9:190.
49. Guilbault C, Garant A, Faria S, et al. Long-term outcomes of induction carboplatin and gemcitabine followed by concurrent radiotherapy with low-dose paclitaxel and gemcitabine for stage III non-small-cell lung cancer. *Clin Lung Cancer*. 2017;18(5):565-571.
50. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. *J Clin Oncol*. 2008;26(35):5755-5760.
51. Ahn JS, Ahn YC, Kim J-H, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. *J Clin Oncol*. 2015;33(24):2660-2666.
52. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. *J Clin Oncol*. 2008;26(15):2450-2456.

53. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2014;15(1):59-68.
54. Park SE, Noh JM, Kim YJ, et al. EGFR mutation is associated with short progression-free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy. *Cancer Res Treat.* 2019;51(2):493-501.
55. Xing L, Wu G, Wang L, et al. A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation. *J Clin Oncol.* 2017;35(suppl 15):8531.
56. Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—the ETOP NICOLAS trial. *Lung Cancer.* 2019;133:83-87.
57. Lin S, Lin X, Clay D, et al. OA01.06 DETERRED: Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. *J Thorac Oncol.* 2018;13(10):S320-S321.
58. Ohri N, Cheng H, Jolly S, et al. The selective personalized radioimmunotherapy for locally advanced NSCLC trial (SPRINT). *J Clin Oncol.* 2019;37(suppl 15):TPS8571.
59. Akamatsu H, Harada H, Tokunaga S, et al. A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III non-small-cell lung cancer harboring EGFR mutations (WJOG6911L). *Clin Lung Cancer.* 2019;20(1):e25-e27.
60. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. *J Immunol.* 2005;174(12):7516-7523.
61. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. *J Clin Invest.* 2014;124(2):687-695.
62. Mole RH. Whole body irradiation; radiobiology or medicine? *Br J Radiol.* 1953;26(305):234-241.
63. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity.* 2013;39(1):1-10.
64. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. *Reprod Biol Endocrinol.* 2004;2:4.
65. Wu YL, Park K, Soo RA, et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. *BMC Cancer.* 2011;11:430.
66. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med.* 2017;377(20):1919-1929.
67. Gray JE, Villegas AE, Daniel DB, et al. Three-year overall survival update from the PACIFIC trial. *J Clin Oncol.* 2019;37(suppl 15):8526.
68. Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-Update from PACIFIC. *J Thorac Oncol.* 2020;15(2):288-293.
69. Hui R, Ozguroglu M, Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. *Lancet Oncol.* 2019;20(12):1670-1680.
70. Peters S, Dafni U, Boyer M, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). *Ann Oncol.* 2019;30(2):161-165.
71. Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. *J Thorac Oncol.* 2017;12(2):403-407.

第8章 一线治疗

1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*. 2016;375:1823-1833.
2. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. *N Engl J Med*. 2020;383:1328-1339.
3. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*. 2018;378:2078-2092.
4. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med*. 2018;378:2288-2301.
5. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*. 2018;379:2040-2051.
6. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. *J Clin Oncol*. 2018;36:911-919.
7. National Comprehensive Cancer Network. *Non-Small Cell Lung Cancer, version 9*. 2020. Available at: nccn.org. Accessed September 11, 2020.
8. Peters S, Reck M, Smit E, et al. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. *Ann Oncol*. 2019;30:884-896.
9. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. *Ann Glob Health*. 2019;5:8.
10. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. *Lancet*. 2016;387:1540-1550.
11. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. *J Thorac Oncol*. 2017;12:208-222.
12. Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project. *J Thorac Oncol*. 2018;13:1302-1322.
13. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. *N Engl J Med*. 2015;373:123-135.
14. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*. 2015;373:1627-1639.
15. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*. 2017;389:255-265.
16. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. *N Engl J Med*. 2015;372:2018-2028.
17. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase 3 trial. *Lancet*. 2019;393:1819-1830.
18. Herbst RS, Lopes G, Kowalski DM, et al. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1 positive advanced nonsquamous NSCLC in KEYNOTE-042. *Ann Oncol*. 2019;30:xi63-xi64.
19. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. *N Engl J Med*. 2017;376:2415-2426.

20. Hellmann MD, Paz-Ares L, Berabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small cell lung cancer. *N Engl J Med*. 2019;381:2020-2031.
21. Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. *JAMA Oncol*. 2020;6:661-674.
22. Sezer A, Kilickap S, Gumus M, et al. EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy in advanced non-small cell lung cancer with programmed cell death ligand 1 $\geq 50\%$. *Ann Oncol*. 2020;31(suppl 4):S1142-S1215.
23. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20:924-937.
24. Papadimitrakopoulou V, Cobo M, Bordoni R, et al. OA05.07 IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. *J Thorac Oncol*. 2018;13(suppl 10):S332-S333.
25. Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. *J Thorac Oncol*. 2020;15:1351-1360.
26. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *Lancet Respir Med*. 2019;7:387-401.
27. Astra Zeneca. *Imfinzi and Imfinzi Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for First-Line Treatment of Stage IV Non-Small Cell Lung Cancer* [press release]. Oct 28, 2019. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer.html>. Accessed January 21, 2023.
28. Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology Program by Innovent anti-PD-1-11). *J Thorac Oncol*. 2020;15:1636-1646.
29. Yang Y, Sun J, Wang Z, et al. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. *J Thorac Oncol*. 2021;16(12):2109-2120.
30. Zhou C, Wu L, Fan Y, et al. ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC). *Ann Oncol*. 2020;31(suppl 4):S1142-S1215.
31. Zhou C, Wu L, Fan Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, Phase 3 Trial (ORIENT-12). *J Thorac Oncol*. 2021;16(9):1501-1511.
32. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 Trial. *J Thorac Oncol*. 2022;17(2):289-308.
33. Reck M, Ciuleanu TE, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. *J Clin Oncol*. 2020;38(suppl 15):9501.
34. Paz-Ares LG, Ciuleanu TE, Cobo-Dols M. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. *J Clin Oncol*. 2022;40(17):LBA9026.
35. Leighl NB, Laurie SA, Goss GD, et al. CCTG BR.34: a randomized trial of durvalumab and tremelimumab $\pm$ platinum-based chemotherapy in patients with metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2020;38(suppl 15):9502.

36. Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase I study. *Lancet Respir Med.* 2019; 7:347-357.
37. Waterhouse DM, Garon EB, Chandler J, et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153. *J Clin Oncol.* 2020;38: 3863-3873.
38. Kazandjian D, Keegan P, Suzman DL, et al. Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. *Semin Oncol.* 2017;44:3-7.
39. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patient with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. *JAMA Oncol.* 2018;4:1543-1552.
40. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol.* 2019;30:1321-1328.
41. Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. *Cancer Discov.* 2018;8:822-835.
42. Arbour KS, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small cell lung cancer. *J Clin Oncol.* 2018;36:2872-2878.
43. Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. *Lancet Oncol.* 2020;21:655-663.
44. Shah NJ, Al-Shbool G, Blackburn M, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. *J Immunother Cancer.* 2019;7:353.
45. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. *J Clin Oncol.* 2008;26(28):4617-4625.
46. Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol.* 2014;15:1254-1262.
47. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. *J Clin Oncol.* 2004;22:3852-3859.
48. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol.* 2008;26:3543-3551.
49. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. *Oncologist.* 2009;14:253-263.
50. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med.* 2002;346:92-98.
51. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med.* 2006;355:2542-2550.
52. Soria JC, Mauguén A, Reck M, et al. Systematic review and meta-analysis of randomized, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer. *Ann Oncol.* 2013;24(1):20-30.
53. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol.* 2004;22:2184-2191.
54. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel +

- carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. *J Thorac Oncol.* 2015;10:134-142.
55. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. *J Clin Oncol.* 2009;27:591-598.
 56. Perol M, Chouaid C, Perol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol.* 2012;30:3516-3524.
 57. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. *Lancet Oncol.* 2010;11:521-529.
 58. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. *Lancet.* 2009;374:1432-1440.
 59. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol.* 2013; 31:2895-2902.
 60. Ramalingam SS, Dahlberg SE, Belani CP, et al. Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer: ECOG-ACRIN 5508. *J Clin Oncol.* 2019;37:2360-2367.

第9章 晚期非小细胞肺癌的二线治疗

1. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. In: Ahmad A, Gadgeel S, eds. *Lung Cancer and Personalized Medicine: Current Knowledge and Therapies*. Cham, Switzerland: Springer International Publishing; 2016:1-19.
2. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol*. 2000;18(10):2095-2103.
3. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. *Lung Cancer*. 2004;43(2):183-194.
4. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol*. 2000;18(12):2354-2362.
5. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol*. 2004;22(9):1589-1597.
6. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. *J Clin Oncol*. 1999;17(7):2081-2085.
7. Di Maio M, Chiodini P, Georgoulas V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. *J Clin Oncol*. 2009;27(11):1836-1843.
8. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet*. 2014;384(9944):665-673.
9. Perol M, Ciuleanu TE, Arrieta O, et al. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. *Lung Cancer*. 2016;93:95-103.
10. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. *Lung Cancer*. 2000;29(1):67-73.
11. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12(4):252-264.
12. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*. 2015;373(2):123-135.
13. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*. 2015;373(17):1627-1639.
14. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016;387(10027):1540-1550.
15. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*. 2017;389(10066):255-265.
16. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced

- non-small-cell lung cancer. *J Clin Oncol.* 2015;33(18):2004-2012.
17. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol.* 2016;11(1):39-51.
 18. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol.* 2015;16(3):257-265.
 19. Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. *Lancet Oncol.* 2019;20(10):1395-1408.
 20. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med.* 2015;372(21):2018-2028.
 21. Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. *J Clin Oncol.* 2019;37(28):2518-2527.
 22. Barlesi F, Garon EB, Kim DW, et al. Health-related quality of life in KEYNOTE-010: a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC. *J Thorac Oncol.* 2019;14(5):793-801.
 23. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. *Clin Cancer Res.* 2012;18(24):6580-6587.
 24. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature.* 2014;515(7528):563-567.
 25. Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase ii open-label study of atezolizumab in PD-L1-selected patients with NSCLC. *J Thorac Oncol.* 2018;13(11):1733-1742.
 26. Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). *J Clin Oncol.* 2017;35(24):2781-2789.
 27. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet.* 2016;387(10030):1837-1846.
 28. Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-pd-l1 antibody avelumab (MSB0010718C) on human tumor cells. *Cancer Immunol Res.* 2015;3(10):1148-1157.
 29. Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. *Lancet Oncol.* 2017;18(5):599-610.
 30. Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. *Lancet Oncol.* 2018;19(11):1468-1479.
 31. Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. *Lancet Oncol.* 2018;19(4):521-536.
 32. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet.* 2019;393(10183):1819-1830.
 33. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. *J Clin Oncol.* 2019;37(7):537-546.
 34. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med.* 2018;378(22):2078-2092.

35. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med*. 2018;378(24):2288-2301.
36. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*. 2018;379(21):2040-2051.
37. Gadgeel SM, Garassino MC, Esteban E, et al. KEYNOTE-189: updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. *J Clin Oncol*. 2019;37(suppl 15):9013.
38. Shiono A, Kaira K, Mouri A, et al. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. *Thorac Cancer*. 2019;10(4):775-781.
39. Schvartsman G, Peng SA, Bis G, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. *Lung Cancer*. 2017;112:90-95.
40. Grigg C, Reuland BD, Sacher AG, Yeh R, Rizvi NA, Shu CA. Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade. *J Clin Oncol*. 2017;35(suppl 15):9082.
41. Tamura N, Horinouchi H, Sekine K, et al. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer. *Thorac Cancer*. 2019;10(5):1141-1148.
42. Leger PD, Rothschild S, Castellanos E, Pillai RN, York SJ, Horn L. Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer. *J Clin Oncol*. 2017;35(suppl 15):9084.
43. Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. *J Thorac Oncol*. 2018;13(1):106-111.
44. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol*. 2015;16(8):908-918.
45. Jacobsoone-Ulrich A, Jamme P, Alkeraye S, et al. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases. *Melanoma Res*. 2016;26(2):153-156.
46. Blasig H, Bender C, Hassel JC, et al. Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. *Melanoma Res*. 2017;27(4):321-325.
47. Cabezas-Camarero S, Cabrera-Martin MN, Perez-Segura P. Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer. *Anticancer Drugs*. 2019;30(2):149-152.
48. Niki M, Nakaya A, Kurata T, et al. Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. *Oncotarget*. 2018;9(64):32298-32304.
49. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. *JAMA Oncol*. 2019;5:1310-1317.
50. Bernard-Tessier A, Baldini C, Martin P, et al. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. *Eur J Cancer*. 2018;101:160-164.
51. Reckamp KL, Redman MW, Dragnev KH, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. *J Clin Oncol*. 2022;40:2295-2306.

第 10 章 缺漏表皮生长因子受体突变非小细胞肺癌:临床治疗策略

1. Shi Y, Au JSK, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). *J Thorac Oncol*. 2014;9(2):154-162.
2. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer. *N Engl J Med*. 2008;359(13):1367-80.
3. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. *Cancer Res*. 1993;53(suppl 10):2379-2385.
4. Lee CK, Wu YL, Ding PN, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. *J Clin Oncol*. 2015;33(17):1958-1965.
5. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol*. 2015;16(2):141-151.
6. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. *N Engl J Med*. 2019;382(1):41-50.
7. Truini A, Starrett JH, Stewart T, et al. The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma. *Clin Cancer Res*. 2019;25(21):6382-6391.
8. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline update. *J Clin Oncol*. 2018;36:911-919.
9. Hitij NT, Kern I, Sadikov A, et al. Immunohistochemistry for EGFR mutation detection in non-small-cell lung cancer. *Clin Lung Cancer*. 2017;18(3):e187-e196.
10. Brown P. The Cobas® EGFR Mutation Test v2 assay. *Future Oncol*. 2016;12(4):451-452.
11. FDA Fact Sheet Approach to Tumor Profiling Next Generation Sequencing Tests. 2018. Available at: <https://www.fda.gov/media/109050/download>. Accessed August 1, 2019.
12. Moding EJ, Diehn M, Wakelee HA. Circulating tumor DNA testing in advanced non-small cell lung cancer. *Lung Cancer*. 2018;119:42-47.
13. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. *J Thorac Oncol*. 2018;13(9):1248-1268.
14. Wu YL, Lee V, Liang CK, et al. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. *Lung Cancer*. 2018;126:1-8.
15. Reck M, Hagiwara K, Han B, et al. CtDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study. *J Thorac Oncol*. 2016;11(10):1682-1689.
16. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. *Clin Cancer Res*. 2019;25(15):4691-4700.
17. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. *Clin Cancer Res*. 2014;20(6):1698-1705.
18. Mok T, Wu YL, Lee JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. *Clin Cancer Res*. 2015;21(14):3196-3203.

19. Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? *Nat Rev Clin Oncol.* 2018;15(11): 694-708.
20. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. *Clin Cancer Res.* 2013;19(8): 2240-2247.
21. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med.* 2017;376(7):629-640.
22. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med.* 2018;378(2):113-125.
23. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. *J Natl Cancer Inst.* 2022;166:9-16.
24. Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. *J Clin Oncol.* 2018;36(22):2244-2250.
25. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med.* 2009;361(10):947-957.
26. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol.* 2011;29(21):2866-2874.
27. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med.* 2010;362(25):2380-2388.
28. Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol.* 2013;24(1):54-59.
29. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol.* 2010;11(2):121-128.
30. Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). *Ann Oncol.* 2015;26(9):1877-1883.
31. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2012;13(3):239-246.
32. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2014;15(2):213-222.
33. Urata Y, Katakami N, Morita S, et al. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. *J Clin Oncol.* 2016;34(27): 3248-3257.
34. Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol.* 2016;17(5):577-589.
35. Paz-Ares L, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. *Ann Oncol.* 2017;28(2):270-277.
36. Yang JCH, Ramalingam SS, Lee CK, et al. 122POsimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): final efficacy and safety results from two phase I expansion cohorts. *Ann Oncol.* 2019;30(suppl 2). doi:10.1093/annonc/mdz063.020.

37. Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. *J Clin Oncol*. 2018;JCO2018783118.doi:10.1200/JCO.2018.78.3118.
38. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017;18(11):1454-1466.
39. Oizumi S, Sugawara S, Minato K, et al. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. *ESMO Open*. 2018;3(2):e000313.
40. Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. *J Clin Oncol*. 2020;38(2):115-123.
41. Noronha V, Joshi A, Patil VM, et al. Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (GEF vs GEF+C). *J Clin Oncol*. 2019;37(suppl 15):9001-9001.
42. Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. *Lancet Oncol*. 2015;16(8):990-998.
43. Mok TSK, Kim SW, Wu YL, et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. *J Clin Oncol*. 2017;35(36):4027-4034.
44. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncol*. 2014;15(11):1236-1244.
45. Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. *Lancet Oncol*. 2019;20(5):625-635.
46. Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study. *Lung Cancer*. 2021;151:20-24.
47. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2019;20(12):1655-1669.
48. Yu HA, Schoenfeld AJ, Makhnin A, et al. Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial. *JAMA Oncol*. 2020;6(7):1048-1054.
49. John T, Akamatsu H, Delmonte A, et al. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. *Lung Cancer*. 2018;126:133-138.
50. Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized Phase III trial (AURA3). *J Clin Oncol*. 2018;36(26):2702-2709.
51. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. *J Clin Oncol*. 2008;26(21):3552-3559.
52. Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. *Cochrane Database Syst Rev*. 2015;(3):CD011430.
53. Cheng H, Li XJ, Wang XJ, et al. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer. *Lung Cancer*. 2019;137:7-13.
54. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment

- for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. *Lancet Oncol.* 2018;19(1):139–148.
55. Wu Y-L, Zhong W, Wang Q, et al. CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1–N2 NSCLC with EGFR mutation—final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. *J Clin Oncol.* 2020;38(15):9005.
 56. Pennell NA, Neal JW, Chaft JE, et al. Select: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. *J Clin Oncol.* 2019;37(2):97–104.
 57. Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage IB–IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, Phase III trial. *J Clin Oncol.* 2015;33(34):4007–4014.
 58. Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. *J Clin Oncol.* 2020; 38(suppl; abstr LBA5), LBA5–LBA5.
 59. Lu S, Casarini I, Kato T, et al. Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage iii non-small-cell lung cancer: LAURA trial in progress. *Clin Lung Cancer.* 2021;22(4):371–375.
 60. Basu Roy U, Elkins IFJ. Impact of an EGFR-lung cancer diagnosis on quality of life of patients: learnings from project PRIORITY. Presented at: International Association for the Study of Lung Cancer (IASLC) 2019 North America Conference on Lung Cancer (NACLC). Chicago, Illinois.
 61. Leighl N, Karaseva N, Nakagawa K, et al. 139PD patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). *J Thorac Oncol.* 2018;13(4):S81–S82.
 62. Califano R, Tariq N, Compton S, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. *Drugs.* 2015;75(12):1335–1348.
 63. Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D, Papp K. Management of EGFR TKI-induced dermatologic adverse events. *Curr Oncol.* 2015;22(2):123–132.
 64. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *J Clin Oncol.* 2010;28(2):357–360.
 65. Tan DS, Yom SS, Tsao MS, et al. The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016. *J Thorac Oncol.* 2016;11(7):946–963.
 66. Xu Q, Liu H, Meng S, et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. *J Cancer.* 2019;10(2):522–529.
 67. Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. *Lung Cancer.* 2015;90(3):509–515.
 68. Lindeman NI, Cagle PT, Aisner DL, Arcila M. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. *Arch Pathol Lab Med* (2018)142(3): 321–346.
 69. Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. *J Clin Oncol.* 2016;34(28):3375–3382.
 70. Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. *Ann Oncol.* 2018;29(suppl 1):i10–i19.
 71. Sequist LV, Lee JS, Han JY, et al. Abstract CT033: TATTON Phase Ib expansion cohort: osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). *Cancer Res.* 2019;79(suppl 13):CT033.
 72. Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. *J Clin Oncol.* 2019;37(4):278–285.

73. Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. *Nat Med*. 2015;21(6):560-562.
74. Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. *Clin Cancer Res*. 2015;21(17):3924-3933.
75. Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. *JAMA Oncol*. 2018;4(11):1527-1534.
76. Papadimitrakopoulou VA, Wu YL, Han JY, et al. LBA51 Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. *Ann Oncol*. 2018. doi:10.1093/annonc/mdy424.064.
77. Ramalingam SS, Cheng Y, Zhou C, Ohe, C. et al. LBA8 Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. *Ann Oncol*. 2018.10.1093/annonc/mdy424.063.
78. Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. *Cancer Discov*. 2014;4(9):1036-1045.
79. Riess J, Groshen S, Reckamp K, et al. Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study. *J Clin Oncol*. 2019;37(15):9057.
80. Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. *J Thorac Oncol*. 2012;7(11):1722-1727.
81. Lo PC, Dahlberg SE, Nishino M, et al. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. *Cancer*. 2015;121(15):2570-2577.
82. Park K, Yu CJ, Kim SW, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. *JAMA Oncol*. 2016;2(3):305-312.
83. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. *J Thorac Oncol*. 2012;7(12):1807-1814.
84. Gomez DR, Blumenschein Jr GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet Oncol*. 2016;17(12):1672-1682.
85. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. *JAMA Oncol*. 2018;4(1):e173501.
86. Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of synchronous oligometastatic non-small cell lung cancer—a consensus report. *J Thorac Oncol*. 2019;14(12):2109-2119.
87. Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. *J Thorac Oncol*. 2018;13(9):1383-1392.
88. Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. EGFR mutation status on brain metastases from non-small cell lung cancer. *Lung Cancer*. 2016;96:101-107.
89. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. *Lung Cancer*. 2015;88(1):108-111.
90. Hu C, Chang EL, Hassenbusch SJ III, et al. Non-small cell lung cancer presenting with synchronous solitary brain metastasis. *Cancer*. 2006;106(9):1998-2004.
91. Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized Phase III trial (AURA3). *J Clin Oncol*. 2018;36(26):2702-2709.
92. Yang JCH, Kim S, Kim D, Lee J. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. *J Clin Oncol*. 2020;38(6):538-547.

93. Arbour KC, Kris MG, Riely GJ, et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases. *Cancer*. 2018;124(1):105-109.
94. Yang JJ, Zhou C, Huang Y, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. *Lancet Respir Med*. 2017;5(9):707-716.
95. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncol*. 2015;16(7):830-838.
96. Cho JH, Lim SH, An HJ, Kim KH. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). *J Clin Oncol*. 2019;38(5):488-495.
97. Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. *Nat Med*. 2018;24(5):638-646.
98. Elamin YY, Robichaux JP, Carter BW, et al. Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. *Cancer Cell*. 2022;40(7):754-767.e6.
99. Janne PA, Neal JW, Camidge DR, et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. *J Clin Oncol*. 2019;37(15):9007.
100. Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial [published correction appears in *JAMA Oncol*. 2022 Feb 24] [published correction appears in *JAMA Oncol*. 2022;8(9):1359]. *JAMA Oncol*. 2021;7(12):e214761.
101. Van Veggel B, Van Der Wekken A, Hashemi S, et al. P2.13-42 osimertinib treatment for patients with EGFR exon 20 insertion positive non-small-cell lung cancer. *J Thorac Oncol*. 2018;13(10):S815.
102. van Veggel B, de Langen AJ, Hashemi SMS, et al. Afatinib and cetuximab in four patients with EGFR exon 20 insertion–positive advanced NSCLC. *J Thorac Oncol*. 2018;13(8):1222-1226.
103. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I Study. *J Clin Oncol*. 2021;39(30):3391-3402.
104. Offin M, Somwar R, Rekhtman N, et al. Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers. *JCO Precis Oncol*. 2018;2:PO.18.00126.
105. Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. *Cancer Discov*. 2018;8(12):1529-1539.
106. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. *Mol Cancer Ther*. 2020;19(10):2044-2056.
107. Shu CA, Goto K, Ohe Yuichiro, et al. Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2. *J Clin Oncol*. 2022;40(16):9006.
108. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. *Cancer Discov*. 2013;3(12):1355-1363.
109. Lee CK, Man J, Lord S, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. *JAMA Oncol*. 2018;4(2):210-216.
110. Lisberg A, Cummings A, Goldman JW, et al. A Phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. *J Thorac Oncol*. 2018;13(8):1138-1145.
111. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-

- cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *Lancet Respir Med*. 2019;7(5):387-401.
112. Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. *Lancet Oncol*. 2018;19(4):521-536.
 113. Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. *JAMA Oncol*. 2018;4(8):1112-1115.
 114. Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. *Ann Oncol*. 2019;30(5):839-844.
 115. Uchida T, Kaira K, Yamaguchi O, et al. Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. *Thorac Cancer*. 2019;10(4):975-979.

第 11 章 间变性淋巴瘤激酶(ALK)重排非小细胞肺癌的诊断与治疗

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*. 2005;353(2):123-132.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004;304(5676):1497-1500.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2004;350(21):2129-2139.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009;361(10):947-957.
5. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*. 2007;448(7153):561-566.
6. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. *Clin Cancer Res*. 2011;17(8):2081-2086.
7. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol*. 2009;27(26):4247-4253.
8. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA*. 2014;311(19):1998-2006.
9. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*. 2010;363(18):1693-1703.
10. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. *Clin Cancer Res*. 2008;14(20):6618-6624.
11. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *J Thorac Oncol*. 2013;8(7):823-859.
12. Lira ME, Kim TM, Huang D, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. *J Mol Diagn*. 2013;15(1):51-61.
13. Shackelford RE, Vora M, Mayhall K, Cotelingam J. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. *Genes Cancer*. 2014;5(1-2):1-14.
14. Uruga H, Mino-Kenudson M. ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. *Pharmgenomics Pers Med*. 2018;11:147-155.
15. Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. *J Thorac Oncol*. 2014;9(5):631-638.
16. Thorne-Nuzzo T, Williams C, Catallini A, et al. A sensitive ALK immunohistochemistry companion diagnostic test identifies patients eligible for treatment with crizotinib. *J Thorac Oncol*. 2017;12(5):804-813.
17. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Arch Pathol Lab Med*. 2018;142(3):321-346.
18. Abel HJ, Al-Kateb H, Cottrell CE, et al. Detection of gene rearrangements in targeted clinical next-generation sequencing. *J Mol Diagn*. 2014;16(4):405-417.
19. Letovanec I, Finn S, Zygoura P, et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European Thoracic Oncology Platform Lungscope

- Project. *J Thorac Oncol*. 2018;13(3):413-425.
20. Ali SM, Hensing T, Schrock AB, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. *Oncologist*. 2016;21(6):762-770.
 21. Abe H, Kawahara A, Azuma K, et al. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples. *J Thorac Oncol*. 2015;10(5):800-805.
 22. Cabillic F, Gros A, Dugay F, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. *J Thorac Oncol*. 2014;9(3):295-306.
 23. Cabillic F, Hofman P, Ilie M, et al. ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question—to treat or not to treat? *ESMO Open*. 2018;3(6):e000419.
 24. Wang Y, Tian PW, Wang WY, et al. Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing. *Oncotarget*. 2016;7(40):65208-65217.
 25. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. *JAMA Oncol*. 2016;2(8):1014-1022.
 26. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. *Clin Cancer Res*. 2019;25(15):4691-4700.
 27. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med*. 2017;377:829-838.
 28. Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. *Lancet*. 2017;390:29-39.
 29. Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. *Lancet Respir Med*. 2019;7(5):437-446.
 30. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. *N Engl J Med*. 2018;379(21):2027-2039.
 31. Soria JC, Tan DS, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet*. 2017;389(10072):917-929.
 32. Hayashi H, Okamoto I, Tanizaki J, et al. Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement. *J Clin Oncol*. 2014;32(36):e122-e124.
 33. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*. 2013;368(25):2385-2394.
 34. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 2014;371(23):2167-2177.
 35. Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. *J Clin Oncol*. 2018;36(22):2251-2258.
 36. Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med*. 2014;370(26):2537-2539.
 37. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. *Lancet Oncol*. 2013;14(7):590-598.
 38. Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. *Lancet Oncol*. 2016;17(12):1683-1696.
 39. Yang Y, Zhou J, Zhou J, et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. *Lancet Respir Med*. 2020;8(1):45-53.

40. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. *J Clin Oncol.* 2017;35(22):2490-2498.
41. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol.* 2016;17(2):234-242.
42. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. *Lancet Oncol.* 2014;15(10):1119-1128.
43. Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol.* 2017;18(12):1590-1599.
44. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol.* 2018;19(12):1654-1667.
45. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med.* 2014;370(13):1189-1197.
46. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. *N Engl J Med.* 2020;383(21):2018-2029.
47. Horn L, Wang Z, Wu G, et al. Phase 3 randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK)-positive NSCLC patients: eXalt3. *World Conference on Lung Cancer Presidential Symposium Abstract 2.* 2020.
48. Nakagawa K, Hida T, Nokihara H, et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. *Lung Cancer.* 2020;139:195-199.
49. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. *Ann Oncol.* 2020;31(8):1056-1064.
50. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. *J Clin Oncol.* 2020;38(31):3592-3603.
51. Cho BC, Kim DW, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). *J Thorac Oncol.* 2017;12(9):1357-1367.
52. Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. *J Clin Oncol.* 2015;33(17):1881-1888.
53. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. *J Clin Oncol.* 2011;29(15):e443-e445.
54. Camidge DR, Kim DW, Tiseo M, et al. Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. *J Clin Oncol.* 2018;36(26):2693-2701.
55. Gadgeel SM, Shaw AT, Govindan R, et al. Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. *J Clin Oncol.* 2016;34(34):4079-4085.
56. Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. *Ann Oncol.* 2018;29(11):2214-2222.
57. Seto T, Nishio M, Hida T, et al. Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). *J Clin Oncol.* 2019;37(suppl 15):9092.
58. Nishio M, Nakagawa K, Mitsudomi T, et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. *Lung Cancer.* 2018;121:37-40.
59. Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-

- oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. *J Med Chem.* 2014;57(11):4720-4744.
60. Gan GN, Weickhardt AJ, Scheier B, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. *Int J Radiat Oncol Biol Phys.* 2014;88(4):892-898.
 61. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. *J Thorac Oncol.* 2012;7(12):1807-1814.
 62. Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. *Cancer Discov.* 2016;6(10):1118-1133.
 63. Hida T, Seto T, Horinouchi H, et al. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9. *Cancer Sci.* 2018;109(9):2863-2872.
 64. Nishio M, Yoshida T, Kumagai T, et al. Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2 J-ALTA trial. *J Thorac Oncol.* 2021;16(3):452-463.
 65. Stinchcombe TE, Doebele RC, Wang X, Gerber DE, Horn L, Camidge DR. Preliminary clinical and molecular analysis results from a single-arm phase 2 trial of brigatinib in patients with disease progression after next-generation ALK tyrosine kinase inhibitors in advanced ALK+ NSCLC. *J Thorac Oncol.* 2021;16(1):156-161.
 66. Horn L, Infante JR, Reckamp KL, et al. Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I/II, multicenter study. *Clin Cancer Res.* 2018;24(12):2771-2779.
 67. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. *J Clin Oncol.* 2018;36(9):911-919.
 68. Ou SI, Lee TK, Young L, et al. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? *Lung Cancer.* 2017;106:110-114.
 69. Takegawa N, Hayashi H, Iizuka N, et al. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. *Ann Oncol.* 2016;27(5):953-955.
 70. Miyamoto S, Ikushima S, Ono R, et al. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. *Jpn J Clin Oncol.* 2016;46(2):170-173.
 71. Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. *J Clin Oncol.* 2019;37(16):1370-1379.
 72. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. *Clin Cancer Res.* 2016;22(18):4585-4593.
 73. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med.* 2018;378(24):2288-2301.
 74. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *Lancet Respir Med.* 2019;7(5):387-401.
 75. Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SI. A user's guide to lorlatinib. *Crit Rev Oncol Hematol.* 2020;151:102969.
 76. Ernani V, Stinchcombe TE. Management of brain metastases in non-small-cell lung cancer. *J Oncol Pract.* 2019;15(11):563-570.

77. Lin JJ, Jiang GY, Joshipura N, et al. Efficacy of alectinib in patients with ALK-positive NSCLC and symptomatic or large CNS metastases. *J Thorac Oncol.* 2019;14(4):683-690.
78. National Institutes of Health. Available at: <https://www.clinicaltrials.gov/>. Accessed September 25, 2019.
79. Zhang C, Li SL, Nie Q, et al. neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement. *J Thorac Oncol.* 2019;14(4):726-731.

第 12 章 其他分子队列包括 *ROS1*, *BRAF*, *HER2*, *MET*, *NTRK*, *RET*, *KRAS*

1. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. *Clin Cancer Res*. 2013;19(15):4040-4045.
2. Stumpfova M, Jänne PA. Zeroing in on ROS1 rearrangements in non-small cell lung cancer. *Clin Cancer Res*. 2012;18(16):4222-4224.
3. Sehgal K, Patell R, Rangachari D, Costa DB. Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. *Transl Cancer Res*. 2018;7(suppl 7):S779-S786.
4. Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. *J Thorac Oncol*. 2019;12(11):1611-1625.
5. Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol*. 2019;30(7):1121-1126.
6. Drilon A, Chiu CH, Fan Y, et al. Long-term efficacy and safety of entrectinib in *ROS1* fusion-positive NSCLC. *JTO Clin Res Rep*. 2022;3(6):100332.
7. Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. *J Clin Oncol*. 2017;35(23):2613-2618.
8. Solomon BJ, Martini JF, Ou SI, Chiari R, Soo RA, Shaw AT. Efficacy of lorlatinib in patients with ROS1-positive advanced non-small cell lung cancer and ROS1 kinase domain mutations. *Ann Oncol*. 2018;29:493-547.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature*. 2002;417(6892):949-954.
10. Chappell WH, Steelman LS, Long JM, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. *Oncotarget*. 2011;2(3):135-164.
11. Brustugun OT, Khattak AM, Tromborg AK, et al. BRAF-mutations in non-small cell lung cancer. *Lung Cancer*. 2014;84(1):36-38.
12. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. *Clin Cancer Res*. 2013;19(16):4532-4540.
13. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. *J Clin Oncol*. 2011;29(15):2046-2051.
14. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. *N Engl J Med*. 2015;373(8):726-736.
15. Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with *B-RAF*^(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. *Lancet Oncol*. 2016;17(5):642-650.
16. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated *B-RAF*^(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol*. 2016;17(7):984-993.
17. Planchard D, Besse B, Groen HJM, et al. Phase 2 study of dabrafenib plus trametinib in patients with *B-RAF*^{V600E}-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. *J Thorac Oncol*. 2022;17(1):103-115.
18. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated *B-RAF*^(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol*. 2017;18(10):1307-1316.
19. Planchard D, Besse B, Groen HJM, et al. Phase 2 study of dabrafenib plus trametinib in patients with *B-RAF*^{V600E}-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. *J Thorac Oncol*. 2022;17(1):103-115.

20. Schadendorf D, Robert C, Dummer R, et al. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. *Eur J Cancer*. 2021;153:234-241.
21. Skead G, Govender D. Gene of the month: MET. *J Clin Pathol*. 2015;68(6):405-409.
22. Drilon A, Cappuzzo F, Ou SHI, Camidge DR. Targeting MET in lung cancer: will expectations finally be MET? *J Thorac Oncol*. 2017;12(1):15-26.
23. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. *Ther Adv Med Oncol*. 2011;3(suppl 1):S7-S19.
24. Salgia R. MET in lung cancer: biomarker selection based on scientific rationale. *Mol Cancer Ther*. 2017;16(4):555-565.
25. Rehman S, Dry G. MET inhibition in non-small cell lung cancer. *Eur Med J*. 2018;4(1):100-111.
26. Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with *MET* exon 14 skipping mutations. *N Engl J Med*. 2020;383(10):931-943.
27. Wolf J, Seto T, Han JY, et al. Capmatinib in *MET* exon 14-mutated or *MET*-amplified non-small-cell lung cancer. *N Engl J Med*. 2020;383(10):944-957.
28. Landi L, Chiari R, Tiseo M, et al. Crizotinib in *MET* deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial. *Clin Cancer Res*. 2019;25:7312-7319.
29. Drilon A, Clark J, Weiss J, et al. OA12.02 Updated antitumor activity of crizotinib in patients with *MET* exon 14-altered advanced non-small cell lung cancer. *J Thorac Oncol*. 2018;13(10):S348.
30. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. *J Pathol*. 1994;172(3):255-260.
31. Ferrara R, Auger N, Auclin E, Besse B. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. *J Thorac Oncol*. 2018;13(1):27-45.
32. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014;511(7511):543-550.
33. Gautschi O, Milia J, Filleron T, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. *J Clin Oncol*. 2017;35(13):1403-1410.
34. Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. *Lancet Oncol*. 2016;17(12):1653-1660.
35. Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. *Ann Oncol*. 2017;28(2):292-297.
36. Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. *Lancet Respir Med*. 2017;5(1):42-50.
37. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study [published correction appears in *Lancet Oncol*. 2021;22(8):e347]. *Lancet Oncol*. 2021;22(7):959-969.
38. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in *RET* fusion-positive non-small-cell lung cancer. *N Engl J Med*. 2020;383(9):813-824.
39. Drilon A, Oxnard G, Wirth L, et al. PL02. 08 registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. *J Thorac Oncol*. 2019;14(10):S6-S7.
40. Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2019;37(suppl 15):9008.
41. Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. *Lung Cancer*. 2015;87(3):220-225.
42. Liu S, Li S, Hai J, et al. Targeting HER2 aberrations in non-small cell lung cancer with osimertinib. *Clin Cancer Res*. 2018;24(11):2594-2604.
43. Auliac JB, Do P, Bayle S, et al. Non-small cell lung cancer patients harboring HER2 mutations:

- clinical characteristics and management in a real-life setting. Cohort HER2 EXPLORE GFPC 02–14. *Adv Ther*. 2019;36(8):2161–2166.
44. Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. *Cancer*. 2017;123(21):4099–4105.
 45. Clamon G, Herndon J, Kern J, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. *Cancer*. 2005; 103(8):1670–1675.
 46. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. *J Clin Oncol*. 2018;36(24):2532–2537.
 47. Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. *Ann Oncol*. 2015;26(7):1421–1427.
 48. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in *HER2*-mutant non-small-cell lung cancer. *N Engl J Med*. 2022;386(3):241–251.
 49. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol*. 2018;15(12):731–747.
 50. Ricciuti B, Brambilla M, Metro G, et al. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. *Med Oncol*. 2017;34(6):105.
 51. Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. *JCO Precis Oncol*. 2018;2018:1–12.
 52. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med*. 2018;378:731–739.
 53. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials [published correction appears in *Lancet Oncol*. 2020 Feb;21(2):e70] [published correction appears in *Lancet Oncol*. 2020 Jul;21(7):e341] [published correction appears in *Lancet Oncol*. 2020 Aug;21(8):e372] [published correction appears in *Lancet Oncol*. 2021 Oct;22(10):e428]. *Lancet Oncol*. 2020;21(2):271–282.
 54. Hyman D, Kummar S, Farago A, et al. Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor. *Cancer Res*. 2019;79:CT127.
 55. Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. *Ann Oncol*. 2021;32(9):1101–1110.
 56. Kempf E, Rousseau B, Besse B, Paz-Ares L. KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. *Eur Respir Rev*. 2016;25(139):71–76.
 57. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with *KRAS* p.G12C Mutation. *N Engl J Med*. 2021;384(25):2371–2381.
 58. Jänne PA, Riely GJ, Gadgil SM, et al. Adagrasib in non-small-cell lung cancer harboring a *KRAS*^{G12C} mutation. *N Engl J Med*. 2022;387(2):120–131.

第 13 章 免疫治疗

1. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer genes. *Nature*. 2013;499(7457):214-218.
2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity*. 2013;39(1):1-10.
3. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012;366(26):2443-2454.
4. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol*. 2015;16(3):257-265.
5. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*. 2015;373(2):123-135.
6. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*. 2015;373:1627-1639.
7. Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. *Lancet Oncol*. 2019;20:1395-1408.
8. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage iv or recurrent non-small-cell lung cancer. *N Engl J Med*. 2017;376(25):2415-2426.
9. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015;372:2018-2028.
10. Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. *Lancet Respir Med*. 2019;7(4):347-357.
11. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016;387(10027):1540-1550.
12. Herbst RS, Garon EB, Kim D-W, Cho BC et al. Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. *Ann Oncol*. 2018;29(suppl 10):42-43.
13. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*. 2016;375(19):1823-1833.
14. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. *J Clin Oncol*. 2019;37(7):537-546.
15. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet*. 2019;393(10183):1819-1830.
16. Horn L, Spigel DR, Gettinger SN, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. *J Clin Oncol*. 2015;33(suppl 15):8029.
17. Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with NSCLC. *J Thorac Oncol*. 2018;13(11):1733-1742.
18. Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). *J Clin Oncol*. 2017;35(24):2781-2789.

19. Carcereny E, Felip E, Reck M, et al. Updated efficacy results from the BIRCH Study: first-line Atezolizumab therapy in PD-L1 selected patients with advanced NSCLC. *J Thorac Oncol.* 2017 12(11):S1791-S1792.
20. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet.* 2016;387(10030):1837-1846.
21. Park K, Lewanski C, Gadgeel S, et al. 3-year survival and duration of response in randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). *J Thorac Oncol.* 2017;12(11):S1840.
22. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet.* 2017;389(10066):255-265.
23. Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. *Nat Med.* 2018;24:1441-1448. doi:10.1038/s41591-018-0134-3. Accessed August 6, 2018.
24. Socinski M, Velcheti V, Mekhail T, Chae TA et al. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutation burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). *Ann Oncol.* 2019;30(suppl 5):919-920.
25. Mok TSK, Gadgeel S, Kim ES, et al. Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC. *Ann Oncol.* 2017;28(suppl 5):494-495.
26. Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. *Lancet Oncol.* 2017;18(5):599-610.
27. Gulley JL, Spigel DR, Kelly K, et al. Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: data from the JAVELIN Solid Tumor trial. *J Clin Oncol.* 2017;35(suppl 15):9086.
28. Reck M, Yang C-H, Postmus PE, et al. JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC). *Ann Oncol.* 2017;28(suppl 5):492.
29. Reck M, Barlesi F, Yang JC-H, et al. Avelumab vs chemotherapy for first-line treatment of advanced PD-L1+ NSCLC: primary analysis from JAVELIN Lung 100. Presented at: International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria.
30. Hellmann MD, Antonia SJ, Balmanoukian AS, et al. Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC. *J Clin Oncol.* 2018;36(suppl 5):169.
31. Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. *Lancet Oncol.* 2018;19(4):521-536.
32. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet.* 2021;397(10274):592-604.
33. Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). *J Immunother Cancer.* 2018;6(1):39.
34. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. *Cancer Immunol Res.* 2015;3(5):436-443.
35. Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. *Lancet Oncol.* 2016;17(3):299-308.
36. Rizvi NA, Chul Cho B, Reinmuth N, et al. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. *Ann Oncol.* 2018;29(suppl 10):40-41.

37. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *Lancet Oncol.* 2017;18(1):31-41.
38. Hellmann MD, Nathanson T, Rizvi H, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. *Cancer Cell.* 2018;33(5):843-852.
39. Ready N, Hellmann MD, Awad MM, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. *J Clin Oncol.* 2019;37(12):992-1000.
40. Hellmann MD, Ciuleanu T, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med.* 2018;378:2093-2104.
41. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. *N Engl J Med.* 2019;381:2020-2031.
42. Borghaei H, Langer CJ, Gadgeel S, et al. 24-Month overall survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. *J Thorac Oncol.* 2019;14(1):124-129.
43. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med.* 2018;378(22):2078-2092.
44. Gadgeel SM, Garassino MC, Esteban E, et al. KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. *J Clin Oncol.* 2019;37:9013.
45. Garassino MC, Rodríguez-Abreu D, Gadgee SM, et al. Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC. *J Clin Oncol.* 2018;36(suppl 15):9021.
46. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med.* 2018;379(21):2040-2051.
47. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med.* 2018;378(24):2288-2301.
48. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2019;20(7):924-937.
49. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst.* 2000;92:205-216.
50. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [published correction appears in *Lancet Oncol.* 2021;22(3):e92]. *Lancet Oncol.* 2021;22(2):198-211.
51. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45(2):228-247.
52. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. *J Immunother.* 2007;30(1):1-15.
53. Nishino M, Giobbie-Hurder A, Gargano M, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. *Clin Cancer Res.* 2013;19:3936-3943.
54. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncol.* 2017;18(3):e143-e152.
55. Hodi FS, Ballinger M, Lyons B, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. *J Clin Oncol.* 2018;36(9):850-858.
56. Hales RK, Banchereau J, Ribas, et al. Assessing oncologic benefit in clinical trials of immunotherapy

- agents. *Ann Oncol*. 2010;21(10):1944-1951.
57. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. *Proc Natl Acad Sci U S A*. 2008;105:3005-3010.
 58. Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. *J Clin Oncol*. 2014;32(suppl 15):9002.
 59. Gandara DR, von Pawel J, Mazieres J, et al. Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK Study. *J Thorac Oncol*. 2018;13(12):1906-1918.
 60. Fujimoto D, Yoshioka H, Kataoka Y, et al. Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy. *J Thorac Oncol*. 2019;14:468-474.
 61. Champiat S, Ferrara R, Massard C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. *Nat Rev Clin Oncol*. 2018;15(12):748-762.
 62. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. *JAMA Oncol*. 2018;4(11):1543-1552.
 63. Saada-Bouazid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol*. 2017;28(7):1605-1611.
 64. Gandara DR, Reck M, Morris S, et al. Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC. *Ann Oncol*. 2018;29(suppl 10):39.
 65. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med*. 2018;378(2):158-168.
 66. Khattri R, Auger JA, Griffin MD, et al. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. *J Immunol*. 1999;162(10):5784-5791.
 67. Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. *Ann Oncol*. 2017;28(10):2377-2385.
 68. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol*. 2010;11(2):155-164.
 69. Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. *Oncologist*. 2017;22(4):470-479.
 70. Chen TW, Razak AR, Bedard PL, et al. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. *Ann Oncol*. 2015;26(9):1824-1829.
 71. Pillai RN, Behera M, Owonikoko TK, et al. Comparison of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of literature. *Cancer*. 2018;124(2):271-277.
 72. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(suppl 4):iv264-iv266.
 73. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2018;36(17):1714-1768.
 74. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2019;17(3):255-289.
 75. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer*. 2017;5(1):95.
 76. Hubbeling HG, Schapira EF, Horick NK, et al. Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. *J Thorac Oncol*. 2018;13(4):550-558.

77. Vansteenkiste J, Naidoo J, Faivre-Finn C, et al. PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT. *J Thorac Oncol.* 2018 13(10):S370-S371.
78. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet.* 2017;389:2492-2502.
79. Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. *JAMA Oncol.* 2019;5(7):1049-1054.

第 14 章 小细胞肺癌

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. *J Clin Oncol*. 2006;24(28):4539-4544.
2. Houston KA, Mitchell KA, King J, White A, Ryan BM. Histologic lung cancer incidence rates and trends vary by race/ethnicity and residential county. *J Thorac Oncol*. 2018;13(4):497-509.
3. Cheng TY, Cramb SM, Baade PD, et al. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. *J Thorac Oncol*. 2016;11(10):1653-1671.
4. Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. *Eur Respir J*. 2004;24(6):898-904.
5. Lassen U, Kristjansen PE, Hansen HH. Brain metastases in small-cell lung cancer. *Ann Oncol*. 1995;6(9):941-944.
6. Thomas A, Pattanayak P, Szabo E, Pinsky P. Characteristics and outcomes of small cell lung cancer detected by CT screening. *Chest*. 2018;154(6):1284-1290.
7. List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. *J Clin Oncol*. 1986;4(8):1191-1198.
8. Shepherd FA, Laskey J, Evans WK, et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. *J Clin Oncol*. 1992;10(1):21-27.
9. Kanaji N, Watanabe N, Kita N, et al. Paraneoplastic syndromes associated with lung cancer. *World J Clin Oncol*. 2014;5(3):197-223.
10. Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. *Mol Cancer*. 2011;10:33.
11. Pulido MA, DerHartunian MK, Qin Z, et al. Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4. *J Neuroimmunol*. 2016;299:70-78.
12. Rekhtman N. Neuroendocrine tumors of the lung: an update. *Arch Pathol Lab Med*. 2010;134(11):1628-1638.
13. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. *Nat Genet*. 2012;44(10):1111-1116.
14. Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nat Genet*. 2012;44(10):1104-1110.
15. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. *Nature*. 2015;524:47.
16. Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. *Nat Rev Cancer*. 2019;19(5):289-297.
17. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med*. 2011;3(75):75ra26.
18. Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and tp53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. *J Thorac Oncol*. 2019;14(10):1784-1793.
19. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol*. 2016;11(1):39-51.
20. Ignatius Ou SH, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM edition. *J Thorac Oncol*. 2009;4(3):300-310.
21. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. *Am J Med*. 1969;46(4):516-525.

22. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? *Lung Cancer*. 2002;37(3):271-276.
23. Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). *Cancer*. 2008;112(8):1827-1834.
24. Wakeam E, Acuna SA, Leighl NB, et al. Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival. *Lung Cancer*. 2017;109:78-88.
25. Inoue M, Miyoshi S, Yasumitsu T, et al. Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. *Ann Thorac Surg*. 2000;70(5):1615-1619.
26. Stinchcombe TE. Current treatments for surgically resectable, limited-stage, and extensive-stage small cell lung cancer. *Oncologist*. 2017;22(12):1510-1517.
27. Yang JC-H, Ou S-HI, De Petris L, et al. Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in—ALK—positive non-small cell lung cancer. *J Thorac Oncol*. 2017;12(10):1552-1560.
28. Wong AT, Rineer J, Schwartz D, Schreiber D. Assessing the impact of postoperative radiation therapy for completely resected limited-stage small cell lung cancer using the National Cancer Database. *J Thorac Oncol*. 2016;11(2):242-248.
29. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. *N Engl J Med*. 1987;316(15):912-918.
30. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. *J Clin Oncol*. 1992;10(6):890-895.
31. Pignon J-P, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. *N Engl J Med*. 1992;327(23):1618-1624.
32. Bogart JA, Herndon JE II, AP Lyss, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. *Int J Radiat Oncol Biol Phys*. 2004;59(2):460-468.
33. Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. *J Clin Oncol*. 1994;12(3):496-502.
34. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. *J Natl Cancer Inst*. 1991;83(12):855-861.
35. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. *J Clin Oncol*. 2002;20(24):4665-4672.
36. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. *J Clin Oncol*. 2012;30(14):1692-1698.
37. Kubota K, Hida T, Ishikura S, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. *Lancet Oncol*. 2014;15(1):106-113.
38. Levitan N, Dowlati A, Shina D, et al. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. *J Clin Oncol*. 2000;18(5):1102.
39. Ettinger DS, Berkey BA, Abrams RA, et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 Phase II Study. *J Clin Oncol*. 2005;23(22):4991-4998.
40. Horn L, Bernardo P, Sandler A, et al. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. *J Thorac Oncol*. 2009;4(4):527-533.

41. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. *J Clin Oncol*. 2009;28(1):43-48.
42. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. *J Clin Oncol*. 2002;20(14):3054-3060.
43. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. 1993;11(2):336-344.
44. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. *J Clin Oncol*. 2004;22(23):4837-4845.
45. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med*. 1999;340(4):265-271.
46. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. *J Clin Oncol*. 1999;17(9):2681-2691.
47. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncol*. 2017;18(8):1116-1125.
48. Corso CD, Rutter CE, Park HS, et al. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. *J Clin Oncol*. 2015;33(36):4240-4246.
49. Christodoulou M, Blackhall F, Mistry H, et al. Compliance and outcome of elderly patients treated in the concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. *J Thorac Oncol*. 2019;14(1):63-71.
50. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. *J Clin Oncol*. 1992;10(2):282-291.
51. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol*. 2006;24(13):2038-2043.
52. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. *J Clin Oncol*. 2009;27(15):2530-2535.
53. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med*. 2018;379(23):2220-2229.
54. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2019;394(10212):1929-1939.
55. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med*. 2002;346(2):85-91.
56. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naïve patients with extensive-disease small-cell lung cancer. *J Clin Oncol*. 2006;24(13):2044-2051.
57. Niell HB, Herndon JE II, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. *J Clin Oncol*. 2005;23(16):3752-3759.
58. Schiller JH, Adak S, Cella D, DeVore RF III, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group. *J Clin Oncol*. 2001;19(8):2114-2122.
59. Sculier JP, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung

- Cancer Working Party. *J Clin Oncol*. 1993;11(10):1858-1865.
60. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. *Cell Rep*. 2013;3(1):246-259.
 61. Armstrong SA, Liu SV. Immune checkpoint inhibitors in small cell lung cancer: a partially realized potential. *Adv Ther*. 2019;36(8):1826-1832.
 62. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. 2015;348(6230):124.
 63. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol*. 2013;24(1):75-83.
 64. Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. *J Clin Oncol*. 2016;34(31):3740-3748.
 65. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med*. 1999;341(7):476-484.
 66. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med*. 2007;357(7):664-672.
 67. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017;18(5):663-671.
 68. Gondi V, Paulus R, Bruner DW, et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. *Int J Radiat Oncol Biol Phys*. 2013;86(4):656-664.
 69. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. *J Clin Oncol*. 1999;17(7):2092-2099.
 70. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. *Lancet*. 2015;385(9962):36-42.
 71. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med*. 2018;379(24):2342-2350.
 72. Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. *J Clin Oncol*. 1988;6(8):1264-1270.
 73. Genestreti G, Tiseo M, Kenmotsu H, et al. Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: a multi-institutional retrospective analysis. *Clin Lung Cancer*. 2015;16(6):e223-e228.
 74. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol*. 1999;17(2):658.
 75. O'Brien MER, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. *J Clin Oncol*. 2006;24(34):5441-5447.
 76. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. *J Clin Oncol*. 2010;28(15):2598-2603.
 77. von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. *J Clin Oncol*. 2014;32(35):4012-4019.
 78. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial [published correction appears in *Lancet Oncol*. 2020;21(12):e553]. *Lancet Oncol*. 2020;21(5):645-654.
 79. Paz-Ares L, Ciuleanu T, Navarro A, et al. PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in relapsed SCLC patients: phase III randomized ATLANTIS trial. *J Thorac Oncol*. 2021;16(10):S844-S845.

80. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol.* 2016;17(7):883-895.
81. Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. *J Thorac Oncol.* 2019;14(2):237-244.
82. Ott PA, Elez E, Hirt S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the Phase IB KEYNOTE-028 Study. *J Clin Oncol.* 2017;35(34):3823-3829.
83. Chung HC, Lopez-Martin JA, Kao SC-H, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. *J Clin Oncol.* 2018;36(suppl 15):8506.
84. Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): results from the KEYNOTE-028 and KEYNOTE-158 studies. *J Thoracic Oncol.* 2020;15(4):618-627.
85. Reck M, Vicente D, Ciuleanu T, et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331. *Ann Oncol.* 2018;29(suppl 10):LBA5-x43.
86. Owonikoko T, Kim HR, Govindan R, et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. *Ann Oncol.* 2019;30(suppl 2):ii77.
87. Bristol Myers Squibb Statement on Opdivo (nivolumab) Small Cell Lung Cancer U.S. Indication. News release. December 29, 2020. Available at: <https://bit.ly/2X5PVFK>. Accessed January 4, 2021.

